{"content":"<li class=\"n-box-item date-title\" data-end=\"1542430799\" data-start=\"1542344400\" data-txt=\"Monday, December 23, 2019\">Friday, November 16, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3410700\" data-ts=\"1542407728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTI\" target=\"_blank\">TTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410700-after-hours-movers-and-shakers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After hours movers and shakers</a></h4><p><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/TTI' title='Tetra Technologies Inc.'>TTI</a> <font color=\"green\">+7%</font>. <a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color=\"green\">+4%</font>. <a href='https://seekingalpha.com/symbol/FTS' title='Fortis, Inc.'>FTS</a> <font color=\"green\">+4%</font>. <a href='https://seekingalpha.com/symbol/COTY' title='Coty Inc.'>COTY</a> <font color=\"green\">+3%</font>. <a href='https://seekingalpha.com/symbol/CKHUF' title='CK Hutchison Holdings LTD'>OTCPK:CKHUF</a> <font color=\"green\">+3%</font>.</p> <p><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/CARB' title='Carbonite Inc.'>CARB</a> <font color=\"red\">-9%</font>. <a href='https://seekingalpha.com/symbol/SSNC' title='SS&C Technologies Holdings, Inc.'>SSNC</a> <font color=\"red\">-4%</font>. <a href='https://seekingalpha.com/symbol/MGI' title='MoneyGram International, Inc.'>MGI</a> <font color=\"red\">-4%</font>. <a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a> <font color=\"red\">-3%</font>. <a href='https://seekingalpha.com/symbol/MHK' title='Mohawk Industries Inc.'>MHK</a> <font color=\"red\">-3%</font>.</p><div class=\"tiny-share-widget\" data-id=\"3410700\" data-linked=\"After hours movers and shakers\" data-tweet=\"$TTI $TTI $IAG - After hours movers and shakers https://seekingalpha.com/news/3410700-after-hours-movers-and-shakers?source=tweet\" data-url=\"https://seekingalpha.com/news/3410700-after-hours-movers-and-shakers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410699\" data-ts=\"1542406770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410699-goldman-bumps-novartis-rating-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman bumps Novartis rating to Buy</a></h4><ul>    <li>Novartis (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) has gotten an upgrade to Buy by Goldman Sachs, from a previous Neutral rating.</li>\n<li>Goldman added the stock to its Conviction Buy list.</li>    <li>That makes for an even split among 30 covering analysts between Buy and Hold ratings, Bloomberg says.</li>    <li>Shares are <font color=\"green\">up 2.7%</font> in late trading amid today's postmarket news, including approval for <a href=\"https://seekingalpha.com/news/3410682-fda-oks-expanded-use-novartis-promacta\" target=\"_blank\">expanded use of the company's Promacta</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410699\" data-linked=\"Goldman bumps Novartis rating to Buy\" data-tweet=\"$NVS - Goldman bumps Novartis rating to Buy https://seekingalpha.com/news/3410699-goldman-bumps-novartis-rating-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3410699-goldman-bumps-novartis-rating-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410697\" data-ts=\"1542406563\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COTY\" target=\"_blank\">COTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410697-cotyplus-3_4-new-ceo-buys-20m-in-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coty +3.4% as new CEO buys $20M in shares</a></h4><ul>   <li>Coty (NYSE:<a href='https://seekingalpha.com/symbol/COTY' title='Coty Inc.'>COTY</a>) is <font color=\"green\">up 3.4%</font> in late trading after a hefty insider buy by its new CEO.</li>    <li>Pierre Laubies bought more than 2.308M shares on Wednesday, according to a <a href=\"https://seekingalpha.com/filing/4242283\" target=\"_blank\">Form 4 filing</a>.</li>    <li>At an average price of $8.6868, that brings the overall purchase to a bit over $20M worth of shares.</li>    <li>The shareholder makes up Laubies' entire holdings of Coty stock.</li>    <li>Meanwhile, JAB Cosmetics, a 10% shareholder, <a href=\"https://seekingalpha.com/filing/4242415\" target=\"_blank\">bought 5.4M shares</a> over three equal purchases over each of the past three days. That total outlay is about $48M.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3408441-coty-announces-new-ceo-board-changes\" target=\"_blank\">Coty announces new CEO and Board changes</a> (Nov. 12 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410697\" data-linked=\"Coty +3.4% as new CEO buys $20M in shares\" data-tweet=\"$COTY - Coty +3.4% as new CEO buys $20M in shares https://seekingalpha.com/news/3410697-cotyplus-3_4-new-ceo-buys-20m-in-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3410697-cotyplus-3_4-new-ceo-buys-20m-in-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410687\" data-ts=\"1542404959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BDRAF\" target=\"_blank\">BDRAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410687-bombardierminus-20-amid-quebec-watchdog-probe-of-executive-stock-trades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bombardier -20% amid Quebec watchdog probe of executive stock trades</a></h4><ul>\n<li>Bombardier (<a href='https://seekingalpha.com/symbol/BDRAF' title='Bombardier Inc.A'>OTCQX:BDRAF</a>, <a href='https://seekingalpha.com/symbol/BDRBF' title='Bombardier Inc.B'>OTCQX:BDRBF</a>) plunged 20% in Toronto trading to its <a href=\"https://business.financialpost.com/news/fp-street/bombardier-probed-by-regulator-over-executive-stock-trades\" target=\"_blank\">lowest level in two years</a> after Quebec\u2019s financial markets regulator <a href=\"https://seekingalpha.com/news/3410367-quebec-regulator-opens-probe-bombardier-stock-program\" target=\"_blank\">said yesterday</a> it was reviewing the company\u2019s executive stock sale program and ordered all such transactions suspended pending the investigation.</li>\n<li>The new scrutiny adds pressure on Bombardier a week after the company lost a quarter of its value since issuing a weak cash flow forecast on Nov. 8, when it said it would only be able to meet its 2018 free cash flow  estimate by using $635M in proceeds from the sale of a Toronto plant  earlier this year.</li>\n<li>Reuters reports top executives including CEO Alain Bellemare and CFO John Di Bert <a href=\"https://www.reuters.com/article/us-bombardier-stocks/bombardier-ceo-meets-investors-as-stock-dives-21-percent-idUSKCN1NL2HU\" target=\"_blank\">met with investors</a> today in Montreal after already meeting with investors in New York and Toronto since Nov. 8.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410687\" data-linked=\"Bombardier -20% amid Quebec watchdog probe of executive stock trades\" data-tweet=\"$BDRAF $BDRAF $BDRBF - Bombardier -20% amid Quebec watchdog probe of executive stock trades https://seekingalpha.com/news/3410687-bombardierminus-20-amid-quebec-watchdog-probe-of-executive-stock-trades?source=tweet\" data-url=\"https://seekingalpha.com/news/3410687-bombardierminus-20-amid-quebec-watchdog-probe-of-executive-stock-trades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410680\" data-ts=\"1542404105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COMM\" target=\"_blank\">COMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410680-commscope-cfo-acquires-748k-in-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CommScope CFO acquires $748K in shares</a></h4><ul><li>CommScope (NASDAQ:<a href='https://seekingalpha.com/symbol/COMM' title='CommScope Holding Company Inc.'>COMM</a>) <font color=\"green\">gains 0.7%</font> aftermarket as EVP and CFO Alexander Pease<a href=\"https://seekingalpha.com/filing/4241972\" target=\"_blank\"> discloses</a> acquiring 40K shares at the average price of about $18.70/share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3410680\" data-linked=\"CommScope CFO acquires $748K in shares\" data-tweet=\"$COMM - CommScope CFO acquires $748K in shares https://seekingalpha.com/news/3410680-commscope-cfo-acquires-748k-in-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3410680-commscope-cfo-acquires-748k-in-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410679\" data-ts=\"1542404086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410679-ziopharm-slips-1-after-hours-following-release-of-early-stage-data-on-gene-therapy-controlled\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ziopharm slips 1% after hours following release of early-stage data on gene therapy Controlled IL-12</a></h4><ul>\n<li>ZIOPHARM Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>) is down <font color=\"red\">1%</font> after hours on the heels it its <a href=\"https://seekingalpha.com/pr/17336816-ziopharm-oncology-provides-controlled-ilminus-12-update-positive-data-phase-1-trial-presented\" target=\"_blank\">announcement </a>of updated data from a Phase 1 clinical trial evaluating gene therapy Controlled IL-12 (Ad-RTS-hIL-12 + veledimex) in patients with recurrent glioblastoma. The results were presented at the Neuro-Oncology Annual Meeting in New Orleans.</li>\n<li>Ad-RTS-hIL-12 combined with a 20 mg dose of veledimex and less than 20 mg of dexamethasone is the optimal regimen. Higher doses of steroids appear to suppress the immune response and adversely affect survival compared to low-dose steroids. A sub-analysis of the data showed median overall survival of 17.8 months in six patients receiving 20 mg or less of dexamethasone compared to a median of 6.4 months in nine patients receiving more than 20 mg.</li>\n<li>A Phase 1 study evaluating Controlled IL-12 + Bristol-Myers Squibb's Opdivo (nivolumab) is now enrolling the second dosing cohort.</li>\n<li>A Phase 2 trial assessing Controlled IL-12 + Regeneron Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) PD-1 inhibitor Libtayo (cemiplimab-rwlc) should commence in H1 2019.</li>\n<li>The company says it is looking for a development partner to advance Controlled IL-12 through registration studies.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410679\" data-linked=\"Ziopharm slips 1% after hours following release of early-stage data on gene therapy Controlled IL-12\" data-tweet=\"$ZIOP $ZIOP $REGN - Ziopharm slips 1% after hours following release of early-stage data on gene therapy Controlled IL-12 https://seekingalpha.com/news/3410679-ziopharm-slips-1-after-hours-following-release-of-early-stage-data-on-gene-therapy-controlled?source=tweet\" data-url=\"https://seekingalpha.com/news/3410679-ziopharm-slips-1-after-hours-following-release-of-early-stage-data-on-gene-therapy-controlled\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410665\" data-ts=\"1542402671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEP\" target=\"_blank\">NEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410665-nextera-energy-partners-affirms-distribution-growth-despite-pg-and-e-projects\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NextEra Energy Partners affirms distribution growth despite PG&amp;E projects</a></h4><ul>\n<li>NextEra Energy Partners (<a href='https://seekingalpha.com/symbol/NEP' title='NextEra Energy Partners, LP'>NEP</a> <font color='green'>+7.4%</font>) racks up strong gains after <a href=\"https://seekingalpha.com/pr/17336014-nextera-energy-partners-meet-investors-early-december\" target=\"_blank\">reaffirming long-term growth expectations</a> for limited partner distributions  without the need to sell common equity until 2020 at the earliest,  regardless of expected contributions from projects that are contracted with Pacific Gas and Electric.</li>\n<li>NEP forecasts EPS of $7.45-$7.95 for 2018, $8.00-$8.50 for 2019, and $8.70-$9.20 for 2020; it expects growth in distributions per share of 12%-14% per year through at least 2020 off a 2017 base of $3.93/share.</li>\n<li><a href=\"http://www.investor.nexteraenergypartners.com/~/media/Files/N/NEP-IR/news-and-events/events-and-presentations/2018/11-15-2018/2018%20December%20Investor%20Presentation_vF.pdf\" target=\"_blank\">Investor presentation</a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410665\" data-linked=\"NextEra Energy Partners affirms distribution growth despite PG&amp;E projects\" data-tweet=\"$NEP - NextEra Energy Partners affirms distribution growth despite PG&amp;E projects https://seekingalpha.com/news/3410665-nextera-energy-partners-affirms-distribution-growth-despite-pg-and-e-projects?source=tweet\" data-url=\"https://seekingalpha.com/news/3410665-nextera-energy-partners-affirms-distribution-growth-despite-pg-and-e-projects\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410662\" data-ts=\"1542402615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTEK\" target=\"_blank\">TTEK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410662-tetra-tech-drops-on-us-attorney-intervention\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tetra Tech drops on US Attorney intervention</a></h4><ul>\n<li>Tetra Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/TTEK' title='Tetra Tech, Inc.'>TTEK</a>) closes today <font color=\"red\">down 1.2%</font> after revealing in a filing that the Civil Division of the United States Attorney's Office intends to intervene in three actions in a district court.</li>\n<li>The complaints allege False Claims Act violations related to environmental remediation contracts at the former Hunters Point Naval Shipyard in San Francisco.</li>\n<li>Qui tam lawsuits are whistleblower lawsuits brought under the FCA, which rewards the whistleblower if the government successfully recovers funds lost to fraud.</li>\n<li>The USAO filed its notice in mid-October and the court ordered it to file a complaint in intervention on or before January 14.</li>\n<li>Tetra says it isn't able to guess at the outcome or potential losses.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410662\" data-linked=\"Tetra Tech drops on US Attorney intervention\" data-tweet=\"$TTEK - Tetra Tech drops on US Attorney intervention https://seekingalpha.com/news/3410662-tetra-tech-drops-on-us-attorney-intervention?source=tweet\" data-url=\"https://seekingalpha.com/news/3410662-tetra-tech-drops-on-us-attorney-intervention\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410641\" data-ts=\"1542402212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCPH\" target=\"_blank\">SCPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410641-scpharmaceuticals-down-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ScPharmaceuticals down 19%</a></h4><ul> <li>Thinly traded nano cap scPharmaceuticals (<a href='https://seekingalpha.com/symbol/SCPH' title='scPharmaceuticals Inc.'>SCPH</a> <font color=\"red\">-19%</font>) ended the session in the red on over four times normal volume, albeit on turnover of only 125K shares. The action took out the bulk of the recent rally.</li> <li>In June, the stock plunged after the FDA <a href=\"https://seekingalpha.com/news/3363584-fda-rejects-scpharmas-furoscix-application-shares-9-percent-premarket\" target=\"_blank\">rejected </a>its marketing application seeking approval for lead candidate FUROSCIX Infusor (furosemide) for the at-home treatment of fluid overload (edema) in heart failure patients. The CRL cited the need for additional human factor studies, device modifications and possibly a new clinical trial.</li> <li>In September, the company met with the FDA to discuss the issues in the CRL. The minutes from the meeting, received a month later, confirmed the need for additional human factor studies and a dose delivery validation study with the recently modified sc2Wear Infusor.</li> <li>The agency also confirmed that the appropriate patient population for the product are those with worsening NYHA Class II and Class III heart failure who show reduced responsiveness to oral diuretics and do not require hospitalization. The labeling, if approved, should state that FUROSCIX should not be used as a substitute for intravenous diuretics for patients who require hospitalization or have been recently discharged (<a href=\"https://www.sec.gov/Archives/edgar/data/1604950/000156459018029140/scph-10q_20180930.htm\" target=\"_blank\">10-Q, page 12</a>).</li> <li>Management will meet with the FDA again on January 9, 2019 to clarify the device delivery validation study protocol.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410641\" data-linked=\"ScPharmaceuticals down 19%\" data-tweet=\"$SCPH - ScPharmaceuticals down 19% https://seekingalpha.com/news/3410641-scpharmaceuticals-down-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3410641-scpharmaceuticals-down-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410648\" data-ts=\"1542401527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTSH\" target=\"_blank\">CTSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410648-cognizantplus-3-on-investor-day-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cognizant +3% on investor day guidance</a></h4><ul>\n<li>Cognizant Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/CTSH' title='Cognizant Technology Solutions Corporation'>CTSH</a>) <font color=\"green\">gains 3.3%</font> on today's investor presentation and its guidance.</li>\n<li>Mid-term financial objectives: Organic revenue CAGR (constant currency), 6% to 9%; 2019 adjusted operating margin, 19% (comparable to the company's previous 22% non-GAAP target).</li>\n<li>Mid-term capital allocation plans: Utilize 60% of FCF annually for dividends, targeting a 20% annual dividend payout ratio and reducing the share count by about 1% annually. The share purchase authorization increases from $3.5B to $5.5B and extends through 2020.</li>\n<li>M&amp;A: CTSH says about 25% of FCF will go towards acquisitions.</li>\n<li>See the full presentation slides <a href=\"https://seekingalpha.com/article/4222922-cognizant-technology-solutions-ctsh-investor-presentation-slideshow\" target=\"_blank\">here</a>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410648\" data-linked=\"Cognizant +3% on investor day guidance\" data-tweet=\"$CTSH - Cognizant +3% on investor day guidance https://seekingalpha.com/news/3410648-cognizantplus-3-on-investor-day-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3410648-cognizantplus-3-on-investor-day-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410629\" data-ts=\"1542400700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKER\" target=\"_blank\">AKER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410629-akers-bio-continues-selloff-down-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akers Bio continues selloff, down 21%</a></h4><ul>\n<li>Nano cap Akers Biosciences (<a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color=\"red\">-21.3%</font>) continues its plunge on 65% higher volume. Shares have lost almost <font color=\"red\">70%</font> of their value since the near-term high of $3.92 on October 30.</li>\n<li>Shares have been in a funk since late March. On April 3, the stock <a href=\"https://seekingalpha.com/news/3343237-akers-biosciences-15-percent-premarket-fy-2017-results\" target=\"_blank\">dropped </a><font color=\"red\">24%</font> after it reported fiscal 2017 results. In May, shares <a href=\"https://seekingalpha.com/news/3359914-akers-bio-34-percent-premarket-withdrawal-u-s-marketing-application-chlamydia-test\" target=\"_blank\">plunged </a>again when the company withdrew its 510(k) application for its PIFA Chlamydia test. Last month, there was a management shakeup and last week a 1:8 reverse stock split. Yesterday, it <a href=\"https://seekingalpha.com/news/3409952-akers-biosciences-q3-revenues-18-percent\" target=\"_blank\">reported </a>an 18% drop in Q3 revenue.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410629\" data-linked=\"Akers Bio continues selloff, down 21%\" data-tweet=\"$AKER - Akers Bio continues selloff, down 21% https://seekingalpha.com/news/3410629-akers-bio-continues-selloff-down-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3410629-akers-bio-continues-selloff-down-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410631\" data-ts=\"1542400082\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HP\" target=\"_blank\">HP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410631-helmerich-payneplus-4-quarterly-revenue-rises-31-y-y\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helmerich &amp; Payne +4% as quarterly revenue rises 31% Y/Y</a></h4><ul>\n<li>Helmerich &amp; Payne (<a href='https://seekingalpha.com/symbol/HP' title='Helmerich & Payne Inc.'>HP</a> <font color='green'>+4.5%</font>) is sharply higher after reporting better than expected <a href=\"https://seekingalpha.com/news/3410345-helmerich-and-payne-eps-line-beats-revenue\" target=\"_blank\">FQ4 earnings</a> and a 31% Y/Y revenue increase to $696M.</li>\n<li>Q4 operating revenue in HP's U.S. Land segment jumped 33% Y/Y to $587M, with average rig revenue per operating day up 11% to $24,449, and average rig margin per day climbing 28% to $10,340; 65% utilization in Q4 vs. 55% in the year-ago quarter helped segment operating income swing to a $64.5M profit from a year-ago loss of $4.2M.</li>\n<li>HP says it expects to see additional demand for its super-spec FlexRigs heading into the new fiscal year as customers continue to push increased lateral lengths and their use of pad drilling; it upgraded 54 FlexRigs to super-spec capacity during FY 2018, including 16 during Q4.</li>\n<li>\"The super-spec rig market in the U.S. is effectively fully utilized, and we continue to see indications that additional demand is forthcoming, even as oil prices have recently moved lower,\" says President and CEO John Lindsay.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410631\" data-linked=\"Helmerich &amp; Payne +4% as quarterly revenue rises 31% Y/Y\" data-tweet=\"$HP - Helmerich &amp; Payne +4% as quarterly revenue rises 31% Y/Y https://seekingalpha.com/news/3410631-helmerich-payneplus-4-quarterly-revenue-rises-31-y-y?source=tweet\" data-url=\"https://seekingalpha.com/news/3410631-helmerich-payneplus-4-quarterly-revenue-rises-31-y-y\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410630\" data-ts=\"1542399848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410630-tesaro-rally-lifts-clovis-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesaro rally lifts Clovis, up 8%</a></h4><ul> <li>Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color=\"green\">+7.8%</font>) is up on 30% higher volume, buoyed by the buyout rumor-stoked rally in PARP competitor TESARO.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410627-tesaro-37-percent-sale-chatter\" target=\"_blank\">Tesaro up 37% on sale chatter</a> (Nov. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410630\" data-linked=\"Tesaro rally lifts Clovis, up 8%\" data-tweet=\"$CLVS - Tesaro rally lifts Clovis, up 8% https://seekingalpha.com/news/3410630-tesaro-rally-lifts-clovis-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3410630-tesaro-rally-lifts-clovis-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410627\" data-ts=\"1542399056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSRO\" target=\"_blank\">TSRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410627-tesaro-up-37-on-sale-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesaro up 37% on sale chatter</a></h4><ul>\n<li>TESARO (<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color=\"green\">+37.3%</font>) is up on modestly higher volume on chatter that it is exploring a sale. This is not the first time rumors of a buyout have circulated. In July, Roche was supposedly <a href=\"https://seekingalpha.com/news/3371944-m-and-rumor-update\" target=\"_blank\">close to a bid</a>, but nothing happened.</li>\n<li>\n<strong>Update</strong>: Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2018-11-16/cancer-drugmaker-tesaro-is-said-to-explore-potential-sale\" target=\"_blank\">reports</a> that the company has engaged financial advisors after receiving takeover interest. The advisors have also started contacting other potential suitors.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410627\" data-linked=\"Tesaro up 37% on sale chatter\" data-tweet=\"$TSRO - Tesaro up 37% on sale chatter https://seekingalpha.com/news/3410627-tesaro-up-37-on-sale-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3410627-tesaro-up-37-on-sale-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410625\" data-ts=\"1542398559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANY\" target=\"_blank\">ANY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410625-technology-movers-sphere-3d-leads-gainers-while-gogo-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology movers: Sphere 3D leads gainers, while Gogo leads the losers</a></h4><ul>\n<li>\n<strong>Gainers: </strong>Sphere 3D (NASDAQ:<a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a>) <font color=\"green\">+31%</font>. Switch (NYSE:<a href='https://seekingalpha.com/symbol/SWCH' title='Switch, Inc.'>SWCH</a>) <font color=\"green\">+12%</font>. SITO Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a>) <font color=\"green\">+11%</font>. ShotSpotter (NASDAQ:<a href='https://seekingalpha.com/symbol/SSTI' title='ShotSpotter'>SSTI</a>) <font color=\"green\">+11%</font>. Digi International (NASDAQ:<a href='https://seekingalpha.com/symbol/DGII' title='Digi International Inc.'>DGII</a>) <font color=\"green\">+9%</font>.</li> <li>\n<strong>Losers: </strong>Gogo (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a>) <font color=\"red\">-22%</font>. NVIDIA (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) <font color=\"red\">-19%</font>. Fang Holdings (NYSE:<a href='https://seekingalpha.com/symbol/SFUN' title='Fang Holdings Ltd. ADS'>SFUN</a>) <font color=\"red\">-12%</font>. Quantum (NYSE:<a href='https://seekingalpha.com/symbol/QTM-OLD' title='Quantum Corporation'>QTM-OLD</a>) <font color=\"red\">-12%</font>. CooTek (NYSE:<a href='https://seekingalpha.com/symbol/CTK' title='CooTek'>CTK</a>) <font color=\"red\">-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410625\" data-linked=\"Technology movers: Sphere 3D leads gainers, while Gogo leads the losers\" data-tweet=\"$ANY $ANY $SWCH - Technology movers: Sphere 3D leads gainers, while Gogo leads the losers https://seekingalpha.com/news/3410625-technology-movers-sphere-3d-leads-gainers-while-gogo-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3410625-technology-movers-sphere-3d-leads-gainers-while-gogo-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410622\" data-ts=\"1542397683\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410622-canadas-supreme-court-to-hear-appeal-in-rio-tinto-innu-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canada&#39;s Supreme Court to hear appeal in Rio Tinto-Innu dispute</a></h4><ul>\n<li>The Supreme Court of Canada <a href=\"http://www.miningweekly.com/article/supreme-court-to-hear-appeal-in-long-running-rio-tinto-ioc-innu-suit-2018-11-16/rep_id:3650\" target=\"_blank\">agrees to hear an appeal</a> by the government of Newfoundland and Labrador on the jurisdiction of Quebec courts in a long-running effort by Innu First Nations in their C$900M lawsuit against Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='green'>+1.9%</font>).</li>\n<li>The government launched the appeal  after Quebec's highest court ruled that the Innu could sue the company and its Iron Ore Co. of  Canada subsidiary through Quebec courts.</li>\n<li>Newfoundland and Labrador argues Quebec courts are  without jurisdiction in the case because the mining operations in question are in  Labrador.</li>\n<li>Iron Ore Co. of Canada rs 59% owned by Rio and is one of the country's largest producers of iron ore.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410622\" data-linked=\"Canada&#39;s Supreme Court to hear appeal in Rio Tinto-Innu dispute\" data-tweet=\"$RIO - Canada&#39;s Supreme Court to hear appeal in Rio Tinto-Innu dispute https://seekingalpha.com/news/3410622-canadas-supreme-court-to-hear-appeal-in-rio-tinto-innu-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3410622-canadas-supreme-court-to-hear-appeal-in-rio-tinto-innu-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410618\" data-ts=\"1542397439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410618-sonnenfeld-facebook-should-replace-dispensable-coo-sandberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sonnenfeld: Facebook should replace &#39;dispensable&#39; COO Sandberg</a></h4><ul>   <li>In the wake of Facebook's (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color=\"red\">-3.2%</font>) defense strategy following a <a href=\"https://seekingalpha.com/news/3409851-nyt-probes-facebooks-crisis-response-delay-deny-deflect-updated\" target=\"_blank\">stinging <i>NYT</i> piece</a> about company leadership, Yale associate dean and management guru Jeffrey Sonnenfeld is calling for a <a href=\"https://www.cnbc.com/2018/11/16/jeffrey-sonnenfeld-facebook-should-probably-replacesheryl-sandberg.html\" target=\"_blank\">shakeup at the top</a> -- referring to COO Sheryl Sandberg as \"completely dispensable\" and saying she probably should be replaced.</li>    <li>Or at least put on probation, he tells CNBC ... and he suggests that CEO Mark Zuckerberg shouldn't be chairman and should instead focus on the CEO role and \"great fixes\" to Facebook's brand, making way for someone like current director Erskine Bowles.</li>    <li>Also on CNBC, New York City Comptroller Scott Stringer (who oversees a pension program holding 4.5M FB shares) agreed about the chairman's role going to someone other than Zuck: \"They're two different responsibilities ... Someone has to oversee the work of Mr. Zuckerberg and Ms. Sandberg.\"</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3410184-fb-board-pushed-execs-move-faster-criticism-unfair\" target=\"_blank\">FB board: We pushed execs to move faster, but criticism is unfair</a> (Nov. 15 2018)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3410029-facebook-responds-nyt-report\" target=\"_blank\">Facebook responds to NYT report</a> (Nov. 15 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410618\" data-linked=\"Sonnenfeld: Facebook should replace &#39;dispensable&#39; COO Sandberg\" data-tweet=\"$FB - Sonnenfeld: Facebook should replace &#39;dispensable&#39; COO Sandberg https://seekingalpha.com/news/3410618-sonnenfeld-facebook-should-replace-dispensable-coo-sandberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3410618-sonnenfeld-facebook-should-replace-dispensable-coo-sandberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>101&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410615\" data-ts=\"1542396165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410615-verizon-acquires-access-control-assets-from-vidder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon acquires access-control assets from Vidder</a></h4><ul>   <li>Verizon (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color=\"green\">+1.8%</font>) is <a href=\"https://seekingalpha.com/pr/17336798-verizon-acquires-software-defined-perimeter-assets-vidder-enhance-enterprise-virtualized\" target=\"_blank\">acquiring key access control assets</a> from Vidder, in order to shore up its virtualized secure networking offering.</li>    <li>Terms weren't disclosed. But Verizon takes over the PrecisionAccess solution along with other assets related to Software Defined Perimeter, a technology designed to protect against online threats by making infrastructure invisible to devices without approved access.</li>    <li>Vidder's technology is already in use in Verizon's SDP offering.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410615\" data-linked=\"Verizon acquires access-control assets from Vidder\" data-tweet=\"$VZ - Verizon acquires access-control assets from Vidder https://seekingalpha.com/news/3410615-verizon-acquires-access-control-assets-from-vidder?source=tweet\" data-url=\"https://seekingalpha.com/news/3410615-verizon-acquires-access-control-assets-from-vidder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410612\" data-ts=\"1542395062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOS\" target=\"_blank\">HOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410612-amyris-and-emerge-energy-services-among-energy-material-sector-losers-hornbeck-offshore\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amyris and Emerge Energy Services among the Energy/Material sector losers; Hornbeck Offshore Services and Gerdau among the gainers</a></h4><ul> <li>\n<b>Gainers: </b>Hornbeck Offshore Services (NYSE:<a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a>) <font color=\"green\">+9%</font>. Gerdau (NYSE:<a href='https://seekingalpha.com/symbol/GGB' title='Gerdau S.A.'>GGB</a>) <font color=\"green\">+7%</font>. BP Prudhoe Bay Royalty Trust (NYSE:<a href='https://seekingalpha.com/symbol/BPT' title='BP Prudhoe Bay Royalty Trust'>BPT</a>) <font color=\"green\">+6%</font>. GeoPark  (NYSE:<a href='https://seekingalpha.com/symbol/GPRK' title='GeoPark Ltd.'>GPRK</a>) <font color=\"green\">+6%</font>. Golden Star Resources (NYSEMKT:<a href='https://seekingalpha.com/symbol/GSS' title='Golden Star Resource Corp'>GSS</a>) <font color=\"green\">+5%</font>.</li> <li>\n<b>Losers: </b>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"red\">-17%</font>. Emerge Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a>) <font color=\"red\">-13%</font>. Contango Oil &amp; Gas (NYSEMKT:<a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a>) <font color=\"red\">-13%</font>. Venator Materials (NYSE:<a href='https://seekingalpha.com/symbol/VNTR' title='Venator Materials'>VNTR</a>) <font color=\"red\">-11%</font>. Smart Sand (NASDAQ:<a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a>) <font color=\"red\">-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410612\" data-linked=\"Amyris and Emerge Energy Services among the Energy/Material sector losers; Hornbeck Offshore Services and Gerdau among the gainers\" data-tweet=\"$HOS $HOS $GGB - Amyris and Emerge Energy Services among the Energy/Material sector losers; Hornbeck Offshore Services and Gerdau among the gainers https://seekingalpha.com/news/3410612-amyris-and-emerge-energy-services-among-energy-material-sector-losers-hornbeck-offshore?source=tweet\" data-url=\"https://seekingalpha.com/news/3410612-amyris-and-emerge-energy-services-among-energy-material-sector-losers-hornbeck-offshore\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410713\" data-ts=\"1542393162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMX\" target=\"_blank\">KMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410713-carmax-growth-estimates-cut-william-blair-sees-weaker-sales-trends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CarMax growth estimates cut as William Blair sees weaker sales trends</a></h4><ul>\n<li>CarMax (<a href='https://seekingalpha.com/symbol/KMX' title='CarMax Group'>KMX</a> <font color='red'>-1.9%</font>) is lower after William Blair research says the company\u2019s sales trends have not  accelerated as quickly as expected, prompting the firm to cut its Q3 used car comp sales growth estimate to 0.5%-1% from  4.5% previously.</li>\n<li>The main factor behind weaker trends is stubbornly high used car prices,  which remained 3%-4% higher in October despite lapping a big spike  during the same time frame last year after Hurricane Harvey, according to Blair.</li>\n<li>The current dislocation in used vs. new pricing could be due to  weaker new car trends and uncertainty on tariff dynamics, resulting in  greater dealer emphasis on used cars, Blair adds.</li>\n<li>Source: Bloomberg First Word</li>\n<li>\n<a href=\"https://seekingalpha.com/news/3410088-carmax-watch-cautious-mention\" target=\"_blank\">Earlier</a>: CarMax on watch after cautious mention (Nov. 16)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410713\" data-linked=\"CarMax growth estimates cut as William Blair sees weaker sales trends\" data-tweet=\"$KMX - CarMax growth estimates cut as William Blair sees weaker sales trends https://seekingalpha.com/news/3410713-carmax-growth-estimates-cut-william-blair-sees-weaker-sales-trends?source=tweet\" data-url=\"https://seekingalpha.com/news/3410713-carmax-growth-estimates-cut-william-blair-sees-weaker-sales-trends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410599\" data-ts=\"1542391372\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRI\" target=\"_blank\">CPRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410599-oppenheimer-cools-on-michael-kors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer cools on Michael Kors</a></h4><ul> <li>Oppenheimer moves to the sidelines on Michael Kors (KORS <font color='red'>-4.1%</font>) after assessing the near-term challenges ahead for the company.</li> <li>\"Ongoing challenges with inventory management and replenishment at the company\u2019s namesake brand and softness within fashion watches will weigh on top-line trends and potentially margins, just as management begins what is likely a significant integration of Versace,\" warns the analyst team.</li> <li>The firm moves to a Perform rating after having KORS set at Outperform.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410599\" data-linked=\"Oppenheimer cools on Michael Kors\" data-tweet=\"$CPRI - Oppenheimer cools on Michael Kors https://seekingalpha.com/news/3410599-oppenheimer-cools-on-michael-kors?source=tweet\" data-url=\"https://seekingalpha.com/news/3410599-oppenheimer-cools-on-michael-kors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410594\" data-ts=\"1542391062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EMCI\" target=\"_blank\">EMCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410594-emc-insurance-leads-financial-gainers-everquote-and-ocwen-financial-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EMC Insurance leads financial gainers; EverQuote and Ocwen Financial among losers</a></h4><ul> <li>\n<b>Gainers:</b> EMC Insurance Group (NASDAQ:<a href='https://seekingalpha.com/symbol/EMCI' title='EMC Insurance Group, Inc.'>EMCI</a>) <font color=\"green\">+30%</font>. Leju Holdings (NYSE:<a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a>) <font color=\"green\">+8%</font>. Innovative Industrial Properties (NYSE:<a href='https://seekingalpha.com/symbol/IIPR' title='Innovative Industrial Properties'>IIPR</a>) <font color=\"green\">+8%</font>. LGI Homes (NASDAQ:<a href='https://seekingalpha.com/symbol/LGIH' title='LGI Homes, Inc.'>LGIH</a>) <font color=\"green\">+7%</font>.</li> <li>\n<b>Losers:</b> Maiden Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a>) <font color=\"red\">-12%</font>. EverQuote (NASDAQ:<a href='https://seekingalpha.com/symbol/EVER' title='EverQuote'>EVER</a>) <font color=\"red\">-9%</font>. The RMR Group (NASDAQ:<a href='https://seekingalpha.com/symbol/RMR' title='The RMR Group Inc.'>RMR</a>) <font color=\"red\">-7%</font>. Summit State Bank (NASDAQ:<a href='https://seekingalpha.com/symbol/SSBI' title='Summit State Bank'>SSBI</a>) <font color=\"red\">-7%</font>. Ocwen Financial (NYSE:<a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410594\" data-linked=\"EMC Insurance leads financial gainers; EverQuote and Ocwen Financial among losers\" data-tweet=\"$EMCI $EMCI $LEJU - EMC Insurance leads financial gainers; EverQuote and Ocwen Financial among losers https://seekingalpha.com/news/3410594-emc-insurance-leads-financial-gainers-everquote-and-ocwen-financial-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3410594-emc-insurance-leads-financial-gainers-everquote-and-ocwen-financial-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410590\" data-ts=\"1542390949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNCE\" target=\"_blank\">CNCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410590-investors-returning-to-tiny-biotechs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors returning to tiny biotechs</a></h4><ul> <li>A number of small biotech &amp; pharma firms are in the green, albeit many on light volume, as bargain hunters move in after the recent selloff.</li> <li>Selected tickers: (<a href='https://seekingalpha.com/symbol/CNCE' title='Concert Pharmaceuticals, Inc.'>CNCE</a> <font color=\"green\">+16.2%</font>)(<a href='https://seekingalpha.com/symbol/CDXS' title='Codexis, Inc.'>CDXS</a> <font color=\"green\">+2.5%</font>)(<a href='https://seekingalpha.com/symbol/CHMA' title='Chiasma'>CHMA</a> <font color=\"green\">+4.1%</font>)(<a href='https://seekingalpha.com/symbol/CCXI' title='ChemoCentryx'>CCXI</a> <font color=\"green\">+2.7%</font>)(<a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color=\"green\">+9.1%</font>)(<a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a> <font color=\"green\">+8.2%</font>)(<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color=\"green\">+4%</font>)(<a href='https://seekingalpha.com/symbol/LIFE' title='aTyr Pharma'>LIFE</a> <font color=\"green\">+9.6%</font>)(<a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color=\"green\">+6.6%</font>)(<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color=\"green\">+5.1%</font>)(<a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color=\"green\">+3.4%</font>)(<a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a> <font color=\"green\">+4.8%</font>)(<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis Inc.'>ADXS</a> <font color=\"green\">+3.7%</font>)(<a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a> <font color=\"green\">+4.3%</font>)(<a href='https://seekingalpha.com/symbol/OCX' title='OncoCyte Corporation'>OCX</a> <font color=\"green\">+3.9%</font>)(<a href='https://seekingalpha.com/symbol/NVLN' title='Novelion Therapeutics, Inc.'>NVLN</a> <font color=\"green\">+6.4%</font>)(<a href='https://seekingalpha.com/symbol/NNVC' title='NanoViricides, Inc.'>NNVC</a> <font color=\"green\">+4.9%</font>)(<a href='https://seekingalpha.com/symbol/IMMY-OLD' title='Imprimis Pharmaceuticals, Inc.'>IMMY-OLD</a> <font color=\"green\">+14.4%</font>)(<a href='https://seekingalpha.com/symbol/IMUC' title='ImmunoCellular Therapeutics, Ltd.'>OTCPK:IMUC</a> <font color=\"green\">+10.9%</font>)(<a href='https://seekingalpha.com/symbol/HEB' title='Hemispherx Biopharma, Inc'>HEB</a> <font color=\"green\">+14.2%</font>)(<a href='https://seekingalpha.com/symbol/EBS' title='Emergent BioSolutions Inc.'>EBS</a> <font color=\"green\">+3.6%</font>)(<a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics'>PTGX</a> <font color=\"green\">+4.5%</font>)(<a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color=\"green\">+6%</font>)(<a href='https://seekingalpha.com/symbol/CPIX' title='Cumberland Pharmaceuticals Inc.'>CPIX</a> <font color=\"green\">+5.3%</font>)(<a href='https://seekingalpha.com/symbol/XENE' title='Xenon Pharmaceuticals'>XENE</a> <font color=\"green\">+2.8%</font>)(<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color=\"green\">+3.3%</font>)(<a href='https://seekingalpha.com/symbol/SBPH' title='Spring Bank Pharmaceuticals'>SBPH</a> <font color=\"green\">+6.7%</font>)(<a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color=\"green\">+6.8%</font>)(<a href='https://seekingalpha.com/symbol/RARX' title='Ra Pharmaceuticals'>RARX</a> <font color=\"green\">+10.4%</font>)(<a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a> <font color=\"green\">+3.9%</font>)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410590\" data-linked=\"Investors returning to tiny biotechs\" data-tweet=\"$CNCE $CNCE $CDXS - Investors returning to tiny biotechs https://seekingalpha.com/news/3410590-investors-returning-to-tiny-biotechs?source=tweet\" data-url=\"https://seekingalpha.com/news/3410590-investors-returning-to-tiny-biotechs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410589\" data-ts=\"1542390809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410589-tech-lunch-break-semis-slip-on-warnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech lunch break: Semis slip on more warnings</a></h4><ul> <li>Semis end the weak battered and red after Nvidia <font color=\"red\">-18%</font> and Applied Materials <font color=\"green\">+1.6%</font> reported downside guidance. Nvidia's drop came as the cryptocurrency boom went bust, previewed in AMD's<font color=\"red\"> -5.2% </font>preceding earnings report, with a correction in the gaming business. Citi attributes AMAT's guide to the US supplier ban on Fujian and mobile display weakness.</li> <li>The tech sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>) and S&amp;P 500 IT Index are relatively flat while the Philadelphia Semiconductor Index <font color=\"red\">drops 1%</font>. The S&amp;P 500 is <font color=\"green\">up 0.3%</font> and Nasdaq down<font color=\"green\"> 0.2%</font>.</li> <li>Related semiconductor ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a>.</li> <li>Top stories from this morning:</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410437-viacom-plus-4-percent-beats-paramount-strength\" target=\"_blank\">Viacom +4% on beats, Paramount strength</a> (Nov. 16)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410536-tsmc-minus-4-percent-morgan-stanley-goes-neutral\" target=\"_blank\">TSMC -4% as Morgan Stanley goes neutral</a> (Nov. 16)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410275-amat-minus-3-percent-downside-guide-near-term-headwinds\" target=\"_blank\">AMAT -3% on downside guide, near-term headwinds</a> (Nov. 15)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410342-chip-stocks-drop-nvidia-report\" target=\"_blank\">Chip stocks drop on Nvidia report</a> (Nov. 15)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410458-citi-defends-amat-earnings\" target=\"_blank\">Citi defends AMAT after earnings</a> (Nov. 16)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410568-semis-storage-move-nvidia-amat-warnings\" target=\"_blank\">Semis, storage move on Nvidia, AMAT warnings</a> (Nov. 16)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410310-nvidia-minus-17-percent-downside-guide-crypto-boom-ends\" target=\"_blank\">Nvidia -17% on downside guide as crypto boom ends</a> (Nov. 15)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410427-goldman-clearly-wrong-nvidia\" target=\"_blank\">Goldman \"clearly wrong\" on Nvidia</a> (Nov. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410589\" data-linked=\"Tech lunch break: Semis slip on more warnings\" data-tweet=\"$XLK $SOXL $SOXX - Tech lunch break: Semis slip on more warnings https://seekingalpha.com/news/3410589-tech-lunch-break-semis-slip-on-warnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3410589-tech-lunch-break-semis-slip-on-warnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410588\" data-ts=\"1542390761\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410588-trump-talks-mueller-china-shares-fluctuate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trump talks Mueller, China; shares fluctuate</a></h4><ul> <li>Speaking to reporters at White House, the president says he's completed answering the special counsel's questions. They weren't difficult, he says, and it didn't take him a long time. Lawyers will review before submission to the Mueller team.</li> <li>On China: We have a great relationship.</li> <li>The S&amp;P 500 is adding modestly to gains, now <font color=\"green\">higher by 0.4%</font>.</li>\n<li>\n<strong>Update at 1:10 ET:</strong> Further comments from the president suggests he's also considering further tariffs against China. Shares are giving back some gains - the S&amp;P 500 and DJIA just barely in the green, and the Nasdaq back in the red.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410588\" data-linked=\"Trump talks Mueller, China; shares fluctuate\" data-tweet=\"Trump talks Mueller, China; shares fluctuate https://seekingalpha.com/news/3410588-trump-talks-mueller-china-shares-fluctuate?source=tweet\" data-url=\"https://seekingalpha.com/news/3410588-trump-talks-mueller-china-shares-fluctuate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410587\" data-ts=\"1542390409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410587-nvidia-gogo-pg-and-e-and-sphere-3d-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NVIDIA , Gogo, PG&amp;E and Sphere 3D among midday movers</a></h4><ul>\n<li>\n<strong>Gainers: </strong>PG&amp;E (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"green\">+36%</font>. Sphere 3D (NASDAQ:<a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a>) <font color=\"green\">+30%</font>. EMC Insurance Group (NASDAQ:<a href='https://seekingalpha.com/symbol/EMCI' title='EMC Insurance Group, Inc.'>EMCI</a>) <font color=\"green\">+30%</font>. Natural Grocers by Vitamin Cottage (NYSE:<a href='https://seekingalpha.com/symbol/NGVC' title='Natural Grocers'>NGVC</a>) <font color=\"green\">+28%</font>. Imprimis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMY-OLD' title='Imprimis Pharmaceuticals, Inc.'>IMMY-OLD</a>) <font color=\"green\">+20%</font>. America's Car-Mart (NASDAQ:<a href='https://seekingalpha.com/symbol/CRMT' title='America&#39;s Car-Mart, Inc.'>CRMT</a>) <font color=\"green\">+16%</font>. Haynes International (NASDAQ:<a href='https://seekingalpha.com/symbol/HAYN' title='Haynes International, Inc.'>HAYN</a>) <font color=\"green\">+15%</font>. Concert Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNCE' title='Concert Pharmaceuticals, Inc.'>CNCE</a>) <font color=\"green\">+14%</font>. Overseas Shipholding Group (NYSE:<a href='https://seekingalpha.com/symbol/OSG' title='Overseas Shipholding Group, Inc.'>OSG</a>) <font color=\"green\">+14%</font>. New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"green\">+13%</font>.</li> <li>\n<strong>Losers: </strong>Limbach Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LMB' title='Limbach Holdings, Inc'>LMB</a>) <font color=\"red\">-30%</font>. Euroseas (NASDAQ:<a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a>) <font color=\"red\">-28%</font>. Hutchison China MediTech (NASDAQ:<a href='https://seekingalpha.com/symbol/HCM' title='Hutchison China MediTech Ltd.'>HCM</a>) <font color=\"red\">-21%</font>. Akers Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a>) <font color=\"red\">-21%</font>. Gogo (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a>) <font color=\"red\">-20%</font>. Acadia Healthcare (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHC' title='Acadia Healthcare Co.'>ACHC</a>) <font color=\"red\">-19%</font>. NVIDIA (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) <font color=\"red\">-19%</font>. RISE Education Cayman (NASDAQ:<a href='https://seekingalpha.com/symbol/REDU' title='RISE Education Cayman Ltd'>REDU</a>) <font color=\"red\">-18%</font>. PHI (NASDAQ:<a href='https://seekingalpha.com/symbol/PHIIK' title='PHI, Inc. - Non'>PHIIK</a>) <font color=\"red\">-16%</font>. AAC Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AAC' title='AAC Holdings, Inc.'>AAC</a>) <font color=\"red\">-15%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410587\" data-linked=\"NVIDIA , Gogo, PG&amp;E and Sphere 3D among midday movers\" data-tweet=\"$PCG $PCG $ANY - NVIDIA , Gogo, PG&amp;E and Sphere 3D among midday movers https://seekingalpha.com/news/3410587-nvidia-gogo-pg-and-e-and-sphere-3d-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3410587-nvidia-gogo-pg-and-e-and-sphere-3d-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410574\" data-ts=\"1542388165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CXW\" target=\"_blank\">CXW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410574-sen-warren-seeks-info-from-corecivic-geo-group-on-federal-compliance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sen. Warren seeks info from CoreCivic, GEO Group on federal compliance</a></h4><ul>\n<li>CoreCivic (<a href='https://seekingalpha.com/symbol/CXW' title='CoreCivic, Inc.'>CXW</a> <font color='red'>-0.5%</font>) turns down and GEO Group (<a href='https://seekingalpha.com/symbol/GEO' title='The GEO Group, Inc.'>GEO</a> <font color='green'>+0.9%</font>) pares earlier gains after Sen. Elizabeth Warren (D-MA), along with a group of other Democratic senators,<a href=\"https://www.warren.senate.gov/newsroom/press-releases/warren-colleagues-implore-private-prison-companies-and-auditor-to-demonstrate-compliance-\" target=\"_blank\"> sent letters</a> to the two publicly traded operators of immigration detention centers requesting information about their compliance with federal immigration and detention standards.</li>\n<li>The letter follows a report from the the Department of Homeland Security Office of the Inspector General about unsafe conditions and mistreatment of immigrants at a number of privately run immigration detention centers, Warren's statement says.</li>\n<li>In their letters, the senators say that the companies lobbied to promote immigration policies that would boost their profits. The Trump administration reversed Obama-era policy to phase out the federal government's reliance on private prisons, the senators say.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3391446-corecivic-gets-new-contract-house-vermont-inmates-mississippi\" target=\"_blank\">CoreCivic gets new contract to house some Vermont inmates in Mississippi</a> (Sept. 19)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410574\" data-linked=\"Sen. Warren seeks info from CoreCivic, GEO Group on federal compliance\" data-tweet=\"$CXW $CXW $GEO - Sen. Warren seeks info from CoreCivic, GEO Group on federal compliance https://seekingalpha.com/news/3410574-sen-warren-seeks-info-from-corecivic-geo-group-on-federal-compliance?source=tweet\" data-url=\"https://seekingalpha.com/news/3410574-sen-warren-seeks-info-from-corecivic-geo-group-on-federal-compliance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410572\" data-ts=\"1542388035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410572-new-age-beverages-leads-consumer-gainers-reeds-and-funko-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages leads consumer gainers; Reed&#39;s and Funko among losers</a></h4><ul> <li>\n<b>Gainers: </b>New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"green\">+12%</font>. Sonos (NASDAQ:<a href='https://seekingalpha.com/symbol/SONO' title='Sonos, Inc.'>SONO</a>) <font color=\"green\">+9%</font>. Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"green\">+9%</font>. Post Holdings (NYSE:<a href='https://seekingalpha.com/symbol/POST' title='Post Holdings, Inc.'>POST</a>) <font color=\"green\">+7%</font>.</li> <li>\n<b>Losers: </b>TDH Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a>) <font color=\"red\">-6%</font>. Reed's (NYSEMKT:<a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a>) <font color=\"red\">-6%</font>. Youngevity International (NASDAQ:<a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a>) <font color=\"red\">-6%</font>. Funko (NASDAQ:<a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a>) <font color=\"red\">-6%</font>. Malibu Boats (NASDAQ:<a href='https://seekingalpha.com/symbol/MBUU' title='Malibu Boats, Inc.'>MBUU</a>) <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410572\" data-linked=\"New Age Beverages leads consumer gainers; Reed&#39;s and Funko among losers\" data-tweet=\"$NBEV $NBEV $SONO - New Age Beverages leads consumer gainers; Reed&#39;s and Funko among losers https://seekingalpha.com/news/3410572-new-age-beverages-leads-consumer-gainers-reeds-and-funko-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3410572-new-age-beverages-leads-consumer-gainers-reeds-and-funko-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410570\" data-ts=\"1542387430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYB\" target=\"_blank\">LYB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410570-reuters-lyondellbasell-near-binding-offer-for-brazils-braskem\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: LyondellBasell near binding offer for Brazil&#39;s Braskem</a></h4><ul> <li>LyondellBasell (<a href='https://seekingalpha.com/symbol/LYB' title='LyondellBasell Industries N.V.'>LYB</a> <font color=\"green\">+1.6%</font>) is <a href=\"https://www.reuters.com/article/us-braskem-m-a-lyondellbasell/lyondellbasell-close-to-binding-offer-for-brazils-braskem-sources-idUSKCN1NL220\" target=\"_blank\">close to presenting a binding offer</a> to acquire control of Brazilian petrochemical company Braskem (<a href='https://seekingalpha.com/symbol/BAK' title='Braskem S.A.'>BAK</a> <font color=\"green\">+1.5%</font>), Reuters reports.</li> <li>LYB is discussing an extension of a long-term naphtha supply contract with Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color=\"green\">+2.3%</font>) seen as pivotal to valuing BAK, and talks between the companies are expected to finish over the next few days, according to the report.</li> <li>PBR reportedly is still discussing whether to sell its full stake in BAK or hold onto shares in the combined company, which would be the world's largest petrochemical company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410570\" data-linked=\"Reuters: LyondellBasell near binding offer for Brazil&#39;s Braskem\" data-tweet=\"$LYB $LYB $BAK - Reuters: LyondellBasell near binding offer for Brazil&#39;s Braskem https://seekingalpha.com/news/3410570-reuters-lyondellbasell-near-binding-offer-for-brazils-braskem?source=tweet\" data-url=\"https://seekingalpha.com/news/3410570-reuters-lyondellbasell-near-binding-offer-for-brazils-braskem\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410568\" data-ts=\"1542387228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410568-semis-storage-move-on-nvidia-amat-warnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semis, storage move on Nvidia, AMAT warnings</a></h4><ul> <li>Semis and storage stocks move after the Nvidia and AMAT earnings reports yesterday both included downside guidance.</li> <li>On the move: (<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a> <font color=\"red\">-2.2%</font>), (<a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage'>PSTG</a> <font color=\"red\">-3.3%</font>), (<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a> <font color=\"red\">-2.8%</font>), (<a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella'>AMBA</a> <font color=\"red\">-5.8%</font>), (<a href='https://seekingalpha.com/symbol/ASML' title='ASML Holding N.V.'>ASML</a> <font color=\"red\">-4.6%</font>), (<a href='https://seekingalpha.com/symbol/BRKS' title='Brooks Automation, Inc.'>BRKS</a> <font color=\"red\">-3.8%</font>), (<a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a> <font color=\"red\">-3.7%</font>), (<a href='https://seekingalpha.com/symbol/XPER' title='Xperi Corporation'>XPER</a> <font color=\"red\">-3.1%</font>), (<a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a> <font color=\"red\">-3%</font>), (<a href='https://seekingalpha.com/symbol/UCTT' title='Ultra Clean Holdings, Inc.'>UCTT</a> <font color=\"red\">-0.3%</font>), (<a href='https://seekingalpha.com/symbol/SNPS' title='Synopsys, Inc.'>SNPS</a> <font color=\"red\">-1.8%</font>), (<a href='https://seekingalpha.com/symbol/TER' title='Teradyne Inc.'>TER</a> <font color=\"red\">-1.4%</font>), (<a href='https://seekingalpha.com/symbol/COHU' title='Cohu, Inc.'>COHU</a> <font color=\"red\">-1.3%</font>), (<a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color=\"red\">-1.5%</font>), (<a href='https://seekingalpha.com/symbol/IPGP' title='IPG Photonics Corporation'>IPGP</a> <font color=\"red\">-0.6%</font>), (<a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a> <font color=\"red\">-0.5%</font>), (<a href='https://seekingalpha.com/symbol/LSCC' title='Lattice Semiconductor Corporation'>LSCC</a> <font color=\"red\">-3.4%</font>), (<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a> <font color=\"red\">-3.5%</font>).</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410342-chip-stocks-drop-nvidia-report\" target=\"_blank\">Chip stocks drop on Nvidia report</a> (Nov. 15)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410427-goldman-clearly-wrong-nvidia\" target=\"_blank\">Goldman \"clearly wrong\" on Nvidia</a> (Nov. 16)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410310-nvidia-minus-17-percent-downside-guide-crypto-boom-ends\" target=\"_blank\">Nvidia -17% on downside guide as crypto boom ends</a> (Nov. 15)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410275-amat-minus-3-percent-downside-guide-near-term-headwinds\" target=\"_blank\">AMAT -3% on downside guide, near-term headwinds</a> (Nov. 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410568\" data-linked=\"Semis, storage move on Nvidia, AMAT warnings\" data-tweet=\"$WDC $WDC $PSTG - Semis, storage move on Nvidia, AMAT warnings https://seekingalpha.com/news/3410568-semis-storage-move-on-nvidia-amat-warnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3410568-semis-storage-move-on-nvidia-amat-warnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410564\" data-ts=\"1542386728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCM\" target=\"_blank\">HCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410564-chi-med-down-21-on-failed-study-of-fruquintinib-in-lung-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chi-Med down 21% on failed study of fruquintinib in lung cancer</a></h4><ul> <li>Thinly traded nano cap Hutchison China MediTech Limited (Chi-Med) (<a href='https://seekingalpha.com/symbol/HCM' title='Hutchison China MediTech Ltd.'>HCM</a> <font color=\"red\">-21.4%</font>) is down on more than a 5x surge in volume following its <a href=\"https://seekingalpha.com/pr/17336262-chi-med-announces-phase-iii-faluca-trial-results-fruquintinib-third-line-advanced-non-small\" target=\"_blank\">announcement </a>of negative results from a Phase 3 clinical trial, FALUCA, evaluating fruquintinib in third-line advanced non-small cell lung cancer &#40;NSCLC&#41;.</li> <li>The study failed to demonstrate a statistically valid increase in overall survival &#40;OS&#41; in the treatment group compared to placebo, the primary endpoint.</li> <li>On the plus side, fruquintinib showed statistically significant increases in the secondary endpoints of progression-free survival &#40;PFS&#41;, objective response rate &#40;ORR&#41;, disease control rate &#40;DCR&#41; and duration of response compared to control.</li> <li>Complete results will be submitted for presentation at a future medical conference.</li> <li>The National Medical Products Administration of China approved fruquintinib, branded as Elunate, in September for advanced colorectal cancer.</li> <li>Fruquintinib starves tumors of their blood supply via inhibiting vascular endothelial growth factor receptors &#40;VEGFR&#41; 1, 2 &amp; 3 which play key roles in tumor-related angiogenesis (formation of new blood vessels).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410564\" data-linked=\"Chi-Med down 21% on failed study of fruquintinib in lung cancer\" data-tweet=\"$HCM - Chi-Med down 21% on failed study of fruquintinib in lung cancer https://seekingalpha.com/news/3410564-chi-med-down-21-on-failed-study-of-fruquintinib-in-lung-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3410564-chi-med-down-21-on-failed-study-of-fruquintinib-in-lung-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410559\" data-ts=\"1542386060\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410559-oracle-acquires-sd-wan-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle acquires SD-WAN company</a></h4><ul>\n<li>Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) continues to gain after yesterday's <a href=\"https://www.oracle.com/corporate/acquisitions/talari/\" target=\"_blank\">acquisition</a> of SD-WAN company Talari Networks.</li>\n<li>Talari's SD-WAN tech offers centralized control and app performance improvements and is used by over 500 customers in 40 countries.</li>\n<li>Talari will enhance Oracle Communications' Session Border Controller and network management infrastructure.</li>\n<li>Terms weren't disclosed.</li>\n<li>Oracle shares are <font color=\"green\">up 1.1%</font> to $51.20.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3409713-berkshire-buys-jpmorgan-oracle-exits-sanofi\" target=\"_blank\">Berkshire buys JPMorgan, Oracle, exits Sanofi</a> (Nov. 14)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410559\" data-linked=\"Oracle acquires SD-WAN company\" data-tweet=\"$ORCL - Oracle acquires SD-WAN company https://seekingalpha.com/news/3410559-oracle-acquires-sd-wan-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3410559-oracle-acquires-sd-wan-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410555\" data-ts=\"1542385811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESEA\" target=\"_blank\">ESEA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410555-euroseas-slides-18_2-on-q3-results-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Euroseas slides 18.2% on Q3 results miss</a></h4><ul> <li>Euroseas (<a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a> <font color=\"red\">-18.2%</font>) reports <a href=\"https://seekingalpha.com/pr/17335967-euroseas-ltd-reports-results-nine-month-period-quarter-ended-september-30-2018\" target=\"_blank\">Q3</a> revenue growth of 59.7% Y/Y to $8.4M.</li> <li>An average of 11 (+22% Y/Y) vessels were owned and operated during Q3 2018, earning an average time charter equivalent rate of $9,704/day (+36.8% Y/Y).</li> <li>Adj. EBITDA was $0.6M (+20% Y/Y) and margin <font color=\"red\">declined 163 bps</font> to 7.14%.</li> <li>Total vessel operating expenses $6,368/day &amp; Time charter equivalent rate was $9,371/day.</li> <li>As of September 30, 2018, outstanding debt was $31.8M versus restricted and unrestricted cash of $4.6M.</li> <li>\u201cOur vessels earned during the quarter rates that on average were ~22% higher than the daily rates earned Y/Y and did we not have the vessel under repair and idle time mentioned above we would likely have turned a positive result for the period.\u201d said Tasos Aslidis, CFO of Euroseas.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410247-euroseas-misses-0_11-misses-revenue\" target=\"_blank\">Euroseas misses by $0.11, misses on revenue</a> (Nov. 15 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410555\" data-linked=\"Euroseas slides 18.2% on Q3 results miss\" data-tweet=\"$ESEA - Euroseas slides 18.2% on Q3 results miss https://seekingalpha.com/news/3410555-euroseas-slides-18_2-on-q3-results-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3410555-euroseas-slides-18_2-on-q3-results-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410552\" data-ts=\"1542385030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEF\" target=\"_blank\">TEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410552-telefonica-closer-to-selling-units-in-mexico-central-america\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telefonica closer to selling units in Mexico, Central America</a></h4><ul>   <li>Telefonica (<a href=\"http://seekingalpha.com/symbol/TEF\" target=\"_blank\">TEF</a> <font color=\"red\">-0.2%</font>) is nearing a sale of its Mexico and Central America units, according to Spain's <i>Expansion.</i>\n</li>    <li>It's in talks with different candidates for the two units, with Cerberus linked as a possibility for the Mexico arm. Meanwhile, Millicom (<a href=\"http://seekingalpha.com/symbol/MIICF\" target=\"_blank\">MIICF</a> <font color=\"green\">+4.4%</font>) says Central American assets would fit, Bloomberg notes.</li>    <li>A sale of the units could come by the end of this year or early next, according to the report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410552\" data-linked=\"Telefonica closer to selling units in Mexico, Central America\" data-tweet=\"$TEF $TEF $TIGO - Telefonica closer to selling units in Mexico, Central America https://seekingalpha.com/news/3410552-telefonica-closer-to-selling-units-in-mexico-central-america?source=tweet\" data-url=\"https://seekingalpha.com/news/3410552-telefonica-closer-to-selling-units-in-mexico-central-america\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410550\" data-ts=\"1542384832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBGL\" target=\"_blank\">SBGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410550-sibanye-ceo-sees-dividends-resumed-2020-after-paying-down-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sibanye CEO sees dividends resumed by 2020 after paying down debt</a></h4><ul>\n<li>Sibanye-Stillwater (<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='green'>+1.7%</font>) plans to <a href=\"https://www.biznews.com/briefs/2018/11/16/debt-dividends-sibanye-ceo-2020\" target=\"_blank\">resume dividends within the next 18 months</a> and consider buying more gold assets after the company pays down its debt, CEO Neal Froneman tells Bloomberg.</li>\n<li>SBGL\u2019s platinum and palladium operations are benefiting from a weaker South African rand, and the Lonmin acquisition will help boost income and speed up debt repayment, Froneman says.</li>\n<li>The CEO's comments show that SBGL, which scrapped dividends a year ago to deal with obligations from major acquisitions, is charting a course back to growth after a disastrous year.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410550\" data-linked=\"Sibanye CEO sees dividends resumed by 2020 after paying down debt\" data-tweet=\"$SBGL - Sibanye CEO sees dividends resumed by 2020 after paying down debt https://seekingalpha.com/news/3410550-sibanye-ceo-sees-dividends-resumed-2020-after-paying-down-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3410550-sibanye-ceo-sees-dividends-resumed-2020-after-paying-down-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410547\" data-ts=\"1542384367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMY-OLD\" target=\"_blank\">IMMY-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410547-imprimis-pharmaceuticals-leads-healthcare-gainers-reshape-lifesciences-and-acadia-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imprimis Pharmaceuticals leads healthcare gainers; ReShape Lifesciences and Acadia Healthcare among losers</a></h4><ul> <li>\n<b>Gainers: </b>Imprimis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMY-OLD' title='Imprimis Pharmaceuticals, Inc.'>IMMY-OLD</a>) <font color=\"green\">+14%</font>. Concert Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNCE' title='Concert Pharmaceuticals, Inc.'>CNCE</a>) <font color=\"green\">+13%</font>. CASI Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a>) <font color=\"green\">+9%</font>. Regulus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a>) <font color=\"green\">+8%</font>. Solid Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences, Inc.'>SLDB</a>) <font color=\"green\">+7%</font>.</li> <li>\n<b>Losers: </b>Acadia Healthcare Company (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHC' title='Acadia Healthcare Co.'>ACHC</a>) <font color=\"red\">-21%</font>. Hutchison China MediTech (NASDAQ:<a href='https://seekingalpha.com/symbol/HCM' title='Hutchison China MediTech Ltd.'>HCM</a>) <font color=\"red\">-21%</font>. Akers Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a>) <font color=\"red\">-15%</font>. ReShape Lifesciences (<a href='https://seekingalpha.com/symbol/RSLS' title='ReShape Lifesciences Inc.'>OTC:RSLS</a>) <font color=\"red\">-10%</font>. Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics, Inc.'>ATOS</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410547\" data-linked=\"Imprimis Pharmaceuticals leads healthcare gainers; ReShape Lifesciences and Acadia Healthcare among losers\" data-tweet=\"$IMMY-OLD $IMMY-OLD $CNCE - Imprimis Pharmaceuticals leads healthcare gainers; ReShape Lifesciences and Acadia Healthcare among losers https://seekingalpha.com/news/3410547-imprimis-pharmaceuticals-leads-healthcare-gainers-reshape-lifesciences-and-acadia-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3410547-imprimis-pharmaceuticals-leads-healthcare-gainers-reshape-lifesciences-and-acadia-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410545\" data-ts=\"1542383821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGEN\" target=\"_blank\">SGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410545-fda-oks-seattle-genetics-adcetris-for-ptcl-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Seattle Genetics&#39; Adcetris for PTCL; shares up 2%</a></h4><ul>\n<li>Under its Real-Time Oncology Review &#40;RTOR&#41; program, the FDA <a href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626079.htm\" target=\"_blank\">approves</a> Seattle Genetics' (<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a> <font color=\"green\">+2.2%</font>) ADCETRIS (brentuximab vedotin), combined with chemo, for the treatment of adult patients with newly diagnosed peripheral T-cell lymphoma in a first-line setting, a Priority Review and Breakthrough Therapy indication.</li>\n<li>RTOR allows the FDA review team to access key data before the company officially files its marketing application in order to quicken the review process. This approval, the first under the program, was issued within two weeks of the completion of the application.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410545\" data-linked=\"FDA OKs Seattle Genetics&#39; Adcetris for PTCL; shares up 2%\" data-tweet=\"$SGEN - FDA OKs Seattle Genetics&#39; Adcetris for PTCL; shares up 2% https://seekingalpha.com/news/3410545-fda-oks-seattle-genetics-adcetris-for-ptcl-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3410545-fda-oks-seattle-genetics-adcetris-for-ptcl-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410544\" data-ts=\"1542383571\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410544-ge-not-inexpensive-given-leverage-profile-goldman-cuts-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE &#39;not inexpensive given leverage profile&#39; as Goldman cuts price target</a></h4><ul> <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color=\"red\">-3.2%</font>) dips back below $8 as Goldman Sachs <a href=\"https://finance.yahoo.com/news/general-electric-beset-too-many-132542134.html\" target=\"_blank\">cuts its price target</a> on the shares to $9 from $12, saying it does not \"see GE as inexpensive given its leverage profile... and tail risk associated with GE Capital.\"</li> <li>A thorough review of GE\u2019s 10-Q still shows more questions than answers around the company, especially because GE Capital could face additional headwinds, says Goldman analyst Joe Ritchie.</li> <li>Goldman sees a chance that the equity infusion from GE to GE Capital could wind up larger than the $3B previously stated for 2019.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410544\" data-linked=\"GE &#39;not inexpensive given leverage profile&#39; as Goldman cuts price target\" data-tweet=\"$GE - GE &#39;not inexpensive given leverage profile&#39; as Goldman cuts price target https://seekingalpha.com/news/3410544-ge-not-inexpensive-given-leverage-profile-goldman-cuts-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3410544-ge-not-inexpensive-given-leverage-profile-goldman-cuts-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>113&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410543\" data-ts=\"1542383265\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410543-bargain-hunters-move-back-biotech\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bargain hunters move back into biotech</a></h4><ul> <li>The SPDR S&amp;P Biotech ETF (<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color=\"green\">+1.5%</font>) is up in early trade, albeit on modest volume, as bargain hunters tiptoe back into biotech. Shares had lost ~<font color=\"red\">25%</font> since early September before reversing yesterday.</li> <li>Selected tickers: (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color=\"green\">+2%</font>)(<a href='https://seekingalpha.com/symbol/FPRX' title='Five Prime Therapeutics, Inc.'>FPRX</a> <font color=\"green\">+1.1%</font>)(<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color=\"green\">+1%</font>)(<a href='https://seekingalpha.com/symbol/UTHR' title='United Therapeutics Corporation'>UTHR</a> <font color=\"green\">+2.8%</font>)(<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a> <font color=\"green\">+2.3%</font>)(<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color=\"green\">+1.1%</font>)(<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a> <font color=\"green\">+3.2%</font>)(<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a> <font color=\"green\">+1.2%</font>)(<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color=\"green\">+2.9%</font>)(<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color=\"green\">+1.7%</font>)(<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos'>GLPG</a> <font color=\"green\">+0.9%</font>)(<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a> <font color=\"green\">+2.5% </font><a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"green\">+0.7%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color=\"green\">+0.8%</font>)(<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences, Inc.'>SLDB</a> <font color=\"green\">+8.9%</font>)(<a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a> <font color=\"green\">+7.8%</font>)(<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a> <font color=\"green\">+2.4%</font>)(<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a> <font color=\"green\">+4.4%</font>)(<a href='https://seekingalpha.com/symbol/QURE' title='uniQure N.V.'>QURE</a> <font color=\"green\">+3.3%</font>)(<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a> <font color=\"green\">+6.5%</font>)(<a href='https://seekingalpha.com/symbol/ADVM' title='Adverum Biotechnologies, Inc.'>ADVM</a> <font color=\"green\">+0.9%</font>)(<a href='https://seekingalpha.com/symbol/IMUC' title='ImmunoCellular Therapeutics, Ltd.'>OTCPK:IMUC</a> <font color=\"green\">+15.6%</font>)(<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color=\"green\">+1.6%</font>)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410543\" data-linked=\"Bargain hunters move back into biotech\" data-tweet=\"$IONS $XBI $IONS - Bargain hunters move back into biotech https://seekingalpha.com/news/3410543-bargain-hunters-move-back-biotech?source=tweet\" data-url=\"https://seekingalpha.com/news/3410543-bargain-hunters-move-back-biotech\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410539\" data-ts=\"1542382809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WAIR\" target=\"_blank\">WAIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410539-wesco-aircraft-slides-14_4-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wesco Aircraft slides 14.4% post Q4 results</a></h4><ul> <li>Wesco Aircraft (<a href='https://seekingalpha.com/symbol/WAIR' title='Wesco Aircraft Holdings'>WAIR</a> <font color=\"red\">-14.4%</font>) reports <a href=\"https://seekingalpha.com/pr/17335966-wesco-aircraft-holdings-reports-fiscal-2018-fourth-quarter-full-year-results\" target=\"_blank\">Q4</a> revenue growth of 12.5% Y/Y to $406.8.M.</li> <li>Overall Q4 margins: Gross <font color=\"green\">increased 9 bps</font> to 24.3%, the increase was primarily due to higher sales volume; operating <font color=\"red\">declined 2 bps</font> to 5.51% &amp; adj. EBITDA <font color=\"green\">increased 61 bps</font> to 9%.</li> <li>SG&amp;A expenses totaled $76.4M (+13.2% Y/Y) the increase was primarily due to costs associated with the company\u2019s Wesco 2020 initiatives.</li> <li>Net cash provided by operating activities totalled $36.9M, an improvement of $31M Y/Y.</li> <li>Free cash flow was $35.3M, compared Y/Y with $3.8M.</li> <li>Improvements in CFO and FCF were primarily due to a decline in inventory investment and an increase in net income.</li> <li>\u201cWe expect Wesco 2020 to generate significant run-rate benefits, with realization in fiscal 2019 to be partially offset by implementation costs. We anticipate full realization of Wesco 2020 benefits to be achieved in fiscal 2020.\u201d said Todd Renehan, CEO.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410267-wesco-aircraft-misses-0_02-beats-revenue\" target=\"_blank\">Wesco Aircraft misses by $0.02, beats on revenue</a> (Nov. 15 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410539\" data-linked=\"Wesco Aircraft slides 14.4% post Q4 results\" data-tweet=\"$WAIR - Wesco Aircraft slides 14.4% post Q4 results https://seekingalpha.com/news/3410539-wesco-aircraft-slides-14_4-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3410539-wesco-aircraft-slides-14_4-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410537\" data-ts=\"1542382647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MATW\" target=\"_blank\">MATW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410537-matthews-internationalplus-9-on-q4-result-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Matthews International +9% on Q4 result beats</a></h4><ul> <li>Matthews International (<a href='https://seekingalpha.com/symbol/MATW' title='Matthews International Corporation'>MATW</a> <font color=\"green\">+9.1%</font>) reported Q4 revenue of $407.4M an increase of 2.9% Y/Y, reflecting the impact of recent acquisitions and organic sales growth in the Industrial Technologies and SGK Brand Solutions segments.</li> <li>Sales by Segments: SGK Brand Solutions $203.5 (-0.1% Y/Y); Memorialization $155.8M (+2.3% Y/Y) and Industrial Technologies $48.1M (+20% Y/Y).</li> <li>Q4 Gross margin <font color=\"red\">declined by 230 bps</font> to 36.5% and operating margin <font color=\"green\">improved by 400 bps</font> to 11.6%.</li> <li>Adj. EBITDA increased 20.1% Y/Y to $77M and margin <font color=\"green\">improved by 272 bps</font> to 18.9%.</li> <li>SG&amp;A expenses decreased by 20.5% Y/Y to $93.26M and margin <font color=\"green\">declined by 673 bps</font> to 22.9%.</li>\n<li>Company reported operating cash flow YTD of $147.6M.</li> <li>For 2019 company expects to achieve growth in Adj. EBITDA in the mid-to-high single digit percentage range and growth in non-GAAP earnings per share in the mid-single digit percentage range over fiscal 2018.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410261-matthews-beats-0_02-beats-revenue\" target=\"_blank\">Matthews beats by $0.02, beats on revenue</a> (Nov. 15)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410259-matthews-declares-0_20-dividend\" target=\"_blank\">Matthews declares $0.20 dividend</a> (Nov. 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410537\" data-linked=\"Matthews International +9% on Q4 result beats\" data-tweet=\"$MATW - Matthews International +9% on Q4 result beats https://seekingalpha.com/news/3410537-matthews-internationalplus-9-on-q4-result-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3410537-matthews-internationalplus-9-on-q4-result-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410536\" data-ts=\"1542382297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSM\" target=\"_blank\">TSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410536-tsmcminus-4-morgan-stanley-goes-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TSMC -4% as Morgan Stanley goes neutral</a></h4><ul>\n<li>Morgan Stanley analyst Charlie Chan <a href=\"https://www.streetinsider.com/Downgrades/Morgan+Stanley+Downgrades+Taiwan+Semiconductor+Manufacturing+Co.+Ltd.+%282330%3ATT%29+%28TSM%29+to+Equalweight/14839263.html\" target=\"_blank\">downgrades</a> TSMC (NYSE:<a href='https://seekingalpha.com/symbol/TSM' title='Taiwan Semiconductor Manufacturing Company Ltd.'>TSM</a>) from Overweight to Equal-weight.</li>\n<li>Last month, the Apple supplier and world's largest contract chipmaker <a href=\"https://asia.nikkei.com/Business/Companies/Apple-supplier-TSMC-cuts-growth-target-again-on-trade-worries\" target=\"_blank\">cut its annual growth target</a> on trade war concerns and the cryptocurrency downturn that was evidenced in yesterday's Nvidia report.</li>\n<li>Apple suppliers including Lumentum and Qorvo have cut guidance this week citing softer orders from a key customer widely believed to be the tech giant. Analysts have cut shipment estimates for the newer iPhones with the XR singled out as an underperforming model.</li>\n<li>TSMC shares are <font color=\"red\">down 4%</font> to $36.99.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3408439-lumentum-drops-q2-guide-shipment-cut\" target=\"_blank\">Lumentum drops Q2 guide on shipment cut</a> (Nov. 12)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3408977-apple-supplier-qorvo-cuts-q3-guidance\" target=\"_blank\">Apple supplier Qorvo cuts Q3 guidance</a> (Nov. 13)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3410310-nvidia-minus-17-percent-downside-guide-crypto-boom-ends\" target=\"_blank\">Nvidia -17% on downside guide as crypto boom ends</a> (Nov. 15)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410536\" data-linked=\"TSMC -4% as Morgan Stanley goes neutral\" data-tweet=\"$TSM - TSMC -4% as Morgan Stanley goes neutral https://seekingalpha.com/news/3410536-tsmcminus-4-morgan-stanley-goes-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3410536-tsmcminus-4-morgan-stanley-goes-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410534\" data-ts=\"1542381702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410534-european-advisory-group-reverses-position-now-backs-amgens-blincyto-for-type-of-all-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group reverses position, now backs Amgen&#39;s Blincyto for type of ALL; shares up 1%</a></h4><ul> <li>The European Medicines Agency's advisory group CHMP has adopted a <a href=\"https://www.ema.europa.eu/documents/smop/chmp-post-authorisation-summary-positive-opinion-blincyto-ii-0011_en.pdf\" target=\"_blank\">positive opinion</a> backing approval for Amgen's (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color=\"green\">+0.6%</font>) BLINCYTO (blinatumomab) for the treatment of  adults with Philadelphia chromosome negative CD19-positive B-precursor acute lymphoblastic leukemia &#40;ALL&#41; in first or second complete remission with minimal residual disease greater than or equal to 0.1%.</li> <li>A couple of months ago, CHMP agreed to re-examine its negative opinion issued in July.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3392135-new-opinions-ema-advisor-chmp\" target=\"_blank\">New opinions from EMA advisor CHMP</a> (Sept. 21)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410534\" data-linked=\"European advisory group reverses position, now backs Amgen&#39;s Blincyto for type of ALL; shares up 1%\" data-tweet=\"$AMGN - European advisory group reverses position, now backs Amgen&#39;s Blincyto for type of ALL; shares up 1% https://seekingalpha.com/news/3410534-european-advisory-group-reverses-position-now-backs-amgens-blincyto-for-type-of-all-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3410534-european-advisory-group-reverses-position-now-backs-amgens-blincyto-for-type-of-all-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410533\" data-ts=\"1542381570\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410533-pg-and-e-surges-40-bankruptcy-fears-ease-citi-uprades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E surges 40% as bankruptcy fears ease, Citi uprades</a></h4><ul> <li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color=\"green\">+39.6%</font>) soars at the open after California Public Utilities Commission chief Michael Picker reportedly  <a href=\"https://seekingalpha.com/news/3410322-pg-and-e-pops-33-percent-hours\" target=\"_blank\">said last night</a> he would not want the company to go bankrupt in the face of billions of dollars in potential liability from the latest California wildfires.</li> <li>But the ~40% surge only recoups yesterday's losses that took the stock as low as $17.26 intraday.</li> <li>Citigroup <a href=\"https://www.cnbc.com/2018/11/15/beleaguered-utility-pge-shares-pop-37percent-after-hours.html\" target=\"_blank\">upgrades PCG shares to Buy</a> from Neutral with a $40 price target, saying the CPUC is \"stepping up now because it is easier for them to come out quickly to support the utility vs. something from the political spectrum.\"</li> <li>\"Why is the CPUC stepping up now vs. mostly looking for legislative initiatives earlier? Given the reaction in the stock market, we think there was an appropriate level of urgency that something needed to be  done,\" Citi writes.</li> <li>At last count, the <a href=\"https://www.cnn.com/2018/11/16/us/california-fires/index.html\" target=\"_blank\">death toll</a> from the Camp Fire has climbed to 63 people with 631 reported missing.</li> <li>Edison International (<a href='https://seekingalpha.com/symbol/EIX' title='Edison International'>EIX</a> <font color=\"green\">+13.9%</font>), which <a href=\"https://www.businesswire.com/news/home/20181115006114/en/SCE-Update-Woolsey-Hill-Wildfires\" target=\"_blank\">provides an update</a> of the fires in southern California, also is sharply higher.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410533\" data-linked=\"PG&amp;E surges 40% as bankruptcy fears ease, Citi uprades\" data-tweet=\"$PCG $PCG $EIX - PG&amp;E surges 40% as bankruptcy fears ease, Citi uprades https://seekingalpha.com/news/3410533-pg-and-e-surges-40-bankruptcy-fears-ease-citi-uprades?source=tweet\" data-url=\"https://seekingalpha.com/news/3410533-pg-and-e-surges-40-bankruptcy-fears-ease-citi-uprades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410532\" data-ts=\"1542381412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRMT\" target=\"_blank\">CRMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410532-americas-car-martplus-13-after-strong-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">America&#39;s Car-Mart +13% after strong Q3</a></h4><ul> <li>America's Car-Mart (NASDAQ:<a href='https://seekingalpha.com/symbol/CRMT' title='America&#39;s Car-Mart, Inc.'>CRMT</a>) is bid <font color=\"green\">up 12.5%</font> after the company cruises past <a href=\"https://seekingalpha.com/pr/17336168-americas-car-mart-reports-diluted-earnings-per-share-1_58-revenues-167-million\" target=\"_blank\">Q3</a> consensus estimates.</li> <li>Same-store revenue was up 11.% during the quarter on a 5.9% lift in the average retail sales price.</li> <li>Gross margin fell 30 bps to 41.7% of sales.</li> <li>Net charge-offs were 6.6% vs. 7.5% a year ago.</li> <li>Shares of CRMT are up 78% YTD.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3410350-americas-car-mart-beats-0_34-beats-revenue\" target=\"_blank\">America's Car-Mart beats by $0.34, beats on revenue</a> (Nov. 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410532\" data-linked=\"America&#39;s Car-Mart +13% after strong Q3\" data-tweet=\"$CRMT - America&#39;s Car-Mart +13% after strong Q3 https://seekingalpha.com/news/3410532-americas-car-martplus-13-after-strong-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3410532-americas-car-martplus-13-after-strong-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410529\" data-ts=\"1542381113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMS\" target=\"_blank\">SGMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410529-scientific-gamesminus-6-jefferies-halves-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scientific Games -6% as Jefferies halves target</a></h4><ul>\n<li>Jefferies <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Jefferies+Downgrades+Scientific+Games+%28SGMS%29+to+Hold/14839691.html\" target=\"_blank\">downgrades</a> Scientific Games (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMS' title='Scientific Games Corp'>SGMS</a>) from Buy to Hold and slices the price target from $46 to $22.</li>\n<li>Earlier this week, Deutsche Bank cut its SGMS target on the recent lukewarm earnings and reported plans to launch an IPO from its social gaming business.</li>\n<li>SGMS is <font color=\"red\">down 6%</font> to $18.76.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3409072-deutsche-cuts-scientific-games-target-ipo-plans\" target=\"_blank\">Deutsche cuts Scientific Games target on IPO plans</a> (Nov. 13)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410529\" data-linked=\"Scientific Games -6% as Jefferies halves target\" data-tweet=\"$SGMS - Scientific Games -6% as Jefferies halves target https://seekingalpha.com/news/3410529-scientific-gamesminus-6-jefferies-halves-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3410529-scientific-gamesminus-6-jefferies-halves-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410526\" data-ts=\"1542380880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABY\" target=\"_blank\">BABY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410526-natus-medical-up-6-on-report-of-starboard-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natus Medical up 6% on report of Starboard stake</a></h4><ul><li>According to Dealreporter, activist Starboard Value <a href=\"https://twitter.com/davidcarnevali/status/1063447829149114369\" target=\"_blank\">has taken a</a> stake in Natus Medical (<a href='https://seekingalpha.com/symbol/BABY' title='Natus Medical Incorporated'>BABY</a> <font color=\"green\">+6%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3410526\" data-linked=\"Natus Medical up 6% on report of Starboard stake\" data-tweet=\"$BABY $NTUS - Natus Medical up 6% on report of Starboard stake https://seekingalpha.com/news/3410526-natus-medical-up-6-on-report-of-starboard-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3410526-natus-medical-up-6-on-report-of-starboard-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410522\" data-ts=\"1542380440\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TI\" target=\"_blank\">TI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410522-report-elliott-directors-lead-in-telecom-italia-ceo-hunt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Elliott directors lead in Telecom Italia CEO hunt</a></h4><ul>   <li>With Amos Genish out as CEO of Telecom Italia (<a href=\"http://seekingalpha.com/symbol/TI\" target=\"_blank\">TI</a> <font color=\"green\">+1.2%</font>) amid a contentious fight for the company between Vivendi (<a href=\"http://seekingalpha.com/symbol/VIVHY\" target=\"_blank\">VIVHY</a> <font color=\"green\">+2%</font>) and Elliott Management, <a href=\"http://telecoms.com/493656/the-two-favourites-for-tim-ceo-job-revealed-source/\" target=\"_blank\">front-runners to replace him</a> are current board members Alfredo Altavilla and Luigi Gubitosi.</li>    <li>That's according to a pro-Vivendi source for Telecoms.com. Those directors were proposed by Elliott during their battle for control of TI with Vivendi earlier this year.</li>    <li>Such a move would seal Elliott's control of the Italian incumbent telecom, with a board majority and the CEO helm.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410522\" data-linked=\"Report: Elliott directors lead in Telecom Italia CEO hunt\" data-tweet=\"$TI $TI $VIVHY - Report: Elliott directors lead in Telecom Italia CEO hunt https://seekingalpha.com/news/3410522-report-elliott-directors-lead-in-telecom-italia-ceo-hunt?source=tweet\" data-url=\"https://seekingalpha.com/news/3410522-report-elliott-directors-lead-in-telecom-italia-ceo-hunt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410520\" data-ts=\"1542380416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410520-groupon-appoints-new-cao\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Groupon appoints new CAO</a></h4><ul>\n<li>Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) <a href=\"https://seekingalpha.com/filing/4240699\" target=\"_blank\">appoints</a> Melissa Thomas as Chief Accounting Officer and Treasurer, effective November 30.</li>\n<li>Thomas replaces Brian Stevens, who announced his resignation to the company on November 8 to pursue a new opportunity.</li>\n<li>Thomas has served as Groupon's VP of Commercial Finance since last year. Previous accounting jobs have included Orbitz and PricewaterhouseCoopers.</li>\n<li>Groupon shares are <font color=\"green\">up 2.8%</font> to $2.93.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410520\" data-linked=\"Groupon appoints new CAO\" data-tweet=\"$GRPN - Groupon appoints new CAO https://seekingalpha.com/news/3410520-groupon-appoints-new-cao?source=tweet\" data-url=\"https://seekingalpha.com/news/3410520-groupon-appoints-new-cao\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410519\" data-ts=\"1542380304\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHC\" target=\"_blank\">ACHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410519-stalled-sale-process-on-acadia-health-cnbc-shares-down-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stalled sale process on Acadia Health - CNBC; shares down 15%</a></h4><ul><li>The sale process for Acadia Healthcare (<a href='https://seekingalpha.com/symbol/ACHC' title='Acadia Healthcare Co.'>ACHC</a> <font color=\"red\">-15.3%</font>) isn't looking promising, reports CNBC's David Faber.</li></ul><div class=\"tiny-share-widget\" data-id=\"3410519\" data-linked=\"Stalled sale process on Acadia Health - CNBC; shares down 15%\" data-tweet=\"$ACHC - Stalled sale process on Acadia Health - CNBC; shares down 15% https://seekingalpha.com/news/3410519-stalled-sale-process-on-acadia-health-cnbc-shares-down-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3410519-stalled-sale-process-on-acadia-health-cnbc-shares-down-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410518\" data-ts=\"1542380283\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLNG\" target=\"_blank\">DLNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410518-dynagas-slumps-to-52-week-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dynagas slumps to 52-week low</a></h4><ul> <li>Dynagas LNG (NYSE:<a href='https://seekingalpha.com/symbol/DLNG' title='Dynagas LNG Partners LP'>DLNG</a>) is <font color=\"red\">down 7.6%</font> after the company misses estimates with its Q3 report.</li> <li>The company's net loss of $0.7M during the quarter included $2.3M of scheduled class survey and dry-docking costs tied to the Yenisei River vessel.</li> <li>Shares of Dynagas traded at a 52-week low of $6.81 earlier in the session.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3410239-dynagas-lng-partners-lp-misses-0_05-misses-revenue\" target=\"_blank\">Dynagas LNG Partners LP misses by $0.05, misses on revenue</a> (Nov. 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410518\" data-linked=\"Dynagas slumps to 52-week low\" data-tweet=\"$DLNG - Dynagas slumps to 52-week low https://seekingalpha.com/news/3410518-dynagas-slumps-to-52-week-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3410518-dynagas-slumps-to-52-week-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410514\" data-ts=\"1542379700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRO\" target=\"_blank\">FRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410514-frontlineplus-2-after-earnings-satisfy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frontline +2% after earnings satisfy</a></h4><ul> <li>Frontline (NYSE:<a href='https://seekingalpha.com/symbol/FRO' title='Frontline Ltd.'>FRO</a>) is <font color=\"green\">up 1.5%</font> after showing a narrower loss in Q3 than anticipated.</li> <li>The company reports a spot TCE of $22K for VLCCs less than 15 years of age in Q3 and guides for a spot TCE of $35K booked for 74% of vessel days for VLCCs less than 15 years of age in Q4.</li>  <li>\"Tanker markets are beginning to rebalance following 18 months of extremely challenging conditions and we are optimistic that the market has now exited the cycle trough,\" says CEO Robert Hvide Macleod.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410394-frontline-beats-0_06-beats-revenue\" target=\"_blank\">Frontline beats by $0.06, beats on revenue</a> (Nov. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410514\" data-linked=\"Frontline +2% after earnings satisfy\" data-tweet=\"$FRO - Frontline +2% after earnings satisfy https://seekingalpha.com/news/3410514-frontlineplus-2-after-earnings-satisfy?source=tweet\" data-url=\"https://seekingalpha.com/news/3410514-frontlineplus-2-after-earnings-satisfy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410496\" data-ts=\"1542378384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NGVC\" target=\"_blank\">NGVC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410496-natural-grocers-gains-after-strong-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural Grocers gains after strong Q3</a></h4><ul> <li>Natural Grocers (NYSE:<a href='https://seekingalpha.com/symbol/NGVC' title='Natural Grocers'>NGVC</a>) is slightly higher after topping consensus estimates with its Q3 report on 10% sales growth.</li> <li>Comparable sales increased 6.3% during the quarter. Adjusted EBITDA rose 10% to $11.3M during the quarter and net income was up 69% to $2.1M.</li> <li>Looking ahead, Natural Grocers expects full-year guidance of $0.33 to $0.40 vs. $0.36 consensus.</li> <li>NGVC <font color=\"green\">+0.6%</font> premarket to $16.76.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3410265-natural-grocers-beats-0_05-beats-revenue\" target=\"_blank\">Natural Grocers beats by $0.05, beats on revenue</a> (Nov. 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410496\" data-linked=\"Natural Grocers gains after strong Q3\" data-tweet=\"$NGVC - Natural Grocers gains after strong Q3 https://seekingalpha.com/news/3410496-natural-grocers-gains-after-strong-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3410496-natural-grocers-gains-after-strong-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410493\" data-ts=\"1542378127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410493-pcg-eix-and-sono-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PCG, EIX and SONO among premarket gainers</a></h4><ul> <li>PG&amp;E (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"green\">+44%</font> after California PUC to <a href=\"https://seekingalpha.com/news/3410372-california-puc-broaden-probe-pg-and-e-including-possible-breakup\" target=\"_blank\">broaden</a> probe including possible breakup.</li> <li>Sonos (NASDAQ:<a href='https://seekingalpha.com/symbol/SONO' title='Sonos, Inc.'>SONO</a>) <font color=\"green\">+18%</font> on <a href=\"https://seekingalpha.com/news/3410242-sonos-beats-0_10-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li> <li>Edison International (NYSE:<a href='https://seekingalpha.com/symbol/EIX' title='Edison International'>EIX</a>) <font color=\"green\">+12%</font>.</li> <li>Aeterna Zentaris (NASDAQ:<a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a>) <font color=\"green\">+10%</font> after <a href=\"https://seekingalpha.com/news/3410481-european-advisory-group-backs-aeterna-zentaris-macrilen-shares-11-percent-premarket\" target=\"_blank\">European advisory</a> group backs Macrilen.</li> <li>Trinity Industries (NYSE:<a href='https://seekingalpha.com/symbol/TRN' title='Trinity Industries Inc.'>TRN</a>) <font color=\"green\">+6%</font> after <a href=\"https://seekingalpha.com/news/3410462-trinity-industries-accelerate-buybacks\" target=\"_blank\">entering</a> into an accelerated share repurchase program with JPMorgan.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410493\" data-linked=\"PCG, EIX and SONO among premarket gainers\" data-tweet=\"$PCG $PCG $SONO - PCG, EIX and SONO among premarket gainers https://seekingalpha.com/news/3410493-pcg-eix-and-sono-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3410493-pcg-eix-and-sono-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410491\" data-ts=\"1542377922\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410491-j-c-penney-sell-argus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.C. Penney a sell at Argus</a></h4><ul> <li>Argus downgrades J.C. Penney (NYSE:<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a>) to a Sell rating after digesting the department store operator's Q3 earnings report.</li> <li>The firm's simple thesis on JCP is based on the expectation for more losses over the next two years.</li> <li>Analyst John Eade: \"We believe that JCP has substantial work ahead, especially in driving sales growth during a period of weak mall traffic and in competing in the very expensive 'arms race' to improve e-commerce capabilities. In addition, the company has posted losses or marginal EPS since 2012 and has consistently missed its own guidance and consensus estimates. Investors should be aware that the current share price below $2 signals elevated risk.\"</li>\n<li>JCP <font color=\"red\">-2.21%</font> premarket to $1.33 after a gain of 11.5% yesterday.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410491\" data-linked=\"J.C. Penney a sell at Argus\" data-tweet=\"$JCP - J.C. Penney a sell at Argus https://seekingalpha.com/news/3410491-j-c-penney-sell-argus?source=tweet\" data-url=\"https://seekingalpha.com/news/3410491-j-c-penney-sell-argus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410489\" data-ts=\"1542377717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESEA\" target=\"_blank\">ESEA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410489-nvda-esea-amat-and-amd-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NVDA, ESEA, AMAT and AMD among premarket losers</a></h4><ul> <li>Euroseas (NASDAQ:<a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a>) <font color=\"red\">-28%</font> on <a href=\"https://seekingalpha.com/news/3410247-euroseas-misses-0_11-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li> <li>NVIDIA (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) <font color=\"red\">-18%</font> on <a href=\"https://seekingalpha.com/news/3410269-nvidia-beats-0_13-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li> <li>Hutchison China MediTech (NASDAQ:<a href='https://seekingalpha.com/symbol/HCM' title='Hutchison China MediTech Ltd.'>HCM</a>) <font color=\"red\">-15%</font> after phase III FALUCA trial for fruquintinib <a href=\"https://seekingalpha.com/news/3410408-chi-meds-phase-iii-faluca-trial-fruquintinib-fails-meet-primary-endpoint-shares-17-percent\" target=\"_blank\">fails</a> to meet primary endpoint.</li> <li>Gogo (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a>) <font color=\"red\">-14%</font> on <a href=\"https://seekingalpha.com/news/3410314-gogo-launches-200m-convertible-debt-offering\" target=\"_blank\">launching</a> $200M convertible debt offering.</li> <li>Contango Oil &amp; Gas Company (NYSEMKT:<a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a>) <font color=\"red\">-14%</font> on <a href=\"https://seekingalpha.com/news/3410482-contango-prices-7_5m-equity-offering\" target=\"_blank\">pricing</a> 7.5M equity offering.</li> <li>Williams-Sonoma (NYSE:<a href='https://seekingalpha.com/symbol/WSM' title='Williams-Sonoma Inc.'>WSM</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3410263-williams-sonoma-beats-0_01-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li> <li>Nordstrom (NYSE:<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a>) <font color=\"red\">-11%</font> on <a href=\"https://seekingalpha.com/news/3410237-nordstrom-beats-0_01-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li> <li>Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>) <font color=\"red\">-9%</font> on <a href=\"https://seekingalpha.com/news/3410230-applied-materials-eps-line-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li> <li>Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) <font color=\"red\">-7%</font>.</li> <li>Sphere 3D (NASDAQ:<a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a>) <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410489\" data-linked=\"NVDA, ESEA, AMAT and AMD among premarket losers\" data-tweet=\"$ESEA $ESEA $NVDA - NVDA, ESEA, AMAT and AMD among premarket losers https://seekingalpha.com/news/3410489-nvda-esea-amat-and-amd-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3410489-nvda-esea-amat-and-amd-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410481\" data-ts=\"1542376878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEZS\" target=\"_blank\">AEZS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410481-european-advisory-group-backs-aeterna-zentaris-macrilen-shares-up-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs Aeterna Zentaris&#39; Macrilen; shares up 11% premarket</a></h4><ul> <li>Nano cap Aeterna Zentaris (NASDAQ:<a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a>) is up <font color=\"green\">11%</font> premarket on increased volume on the heels of a <a href=\"https://www.ema.europa.eu/documents/agenda/agenda-chmp-agenda-12-15-november-2018-meeting_en.pdf\" target=\"_blank\">positive opinion</a> from an advisory group in Europe backing approval for MACRILEN (macimorelin) for the diagnosis of adult growth hormone deficiency.</li> <li>A final decision from the European Commission usually takes ~60 days.</li> <li>The FDA approved MACRILEN almost a year ago.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3319550-fda-oks-aeterna-zentaris-macrilen-diagnosis-adult-growth-hormone-deficiency-shares-53-percent\" target=\"_blank\">FDA OKs Aeterna Zentaris' Macrilen for diagnosis of adult growth hormone deficiency; shares up 53% after hours</a> (Dec. 20, 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410481\" data-linked=\"European advisory group backs Aeterna Zentaris&#39; Macrilen; shares up 11% premarket\" data-tweet=\"$AEZS - European advisory group backs Aeterna Zentaris&#39; Macrilen; shares up 11% premarket https://seekingalpha.com/news/3410481-european-advisory-group-backs-aeterna-zentaris-macrilen-shares-up-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3410481-european-advisory-group-backs-aeterna-zentaris-macrilen-shares-up-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410479\" data-ts=\"1542376853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBRA\" target=\"_blank\">SBRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410479-bofaml-turns-bearish-on-sabra-bullish-on-omega-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML turns bearish on Sabra, bullish on Omega Healthcare</a></h4><ul>\n<li>Sabra Health (NASDAQ:<a href='https://seekingalpha.com/symbol/SBRA' title='Sabra Health Care REIT, Inc.'>SBRA</a>) <font color=\"red\">slips 1.7% </font>in premarket trading after Bank of America Merrill Lynch analysts downgrade the stock to underperform from neutral and trims price target to $21 from $23</li>\n<li>Notes SBRA faces headwinds such as senior care dilution and increased Ridea volatility.</li>\n<li>Cost of capital may be a challenge, especially if it wants to buy its JV partner's stake in Enlivant in late '19 or early '20.</li>\n<li>Omega Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/OHI' title='Omega Healthcare Investors, Inc'>OHI</a>) gets upgraded to neutral from outperform as it completes its Orianna exit in coming months and starts reinvesting proceeds, writes the BofAML analysts led by Juan Sanabria.</li>\n<li>Price target raised to $35.00 from $26.50.</li>\n<li>Notes \"stronger conviction\" that OHI has dealt with most of its tenant issues and is well positioned to boost earnings through acquisitions.</li>\n<li>OHI analyst ratings: 1 buy; 10 holds; 1 underperfom/sell.</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/SBRA/earnings/analyst_ratings\" target=\"_blank\">SBRA analyst ratings</a>: 3 buys; 9 holds; 0 underperform/sells.</li>\n<li>Source: Bloomberg First Word.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3405210-omega-healthcare-plus-4_7-percent-q3-beats-guidance-reaffirmed\" target=\"_blank\">Omega Healthcare +4.7% after Q3 beats, guidance reaffirmed</a> (Nov. 5)</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3405479-sabra-health-care-reit-sinks-3_2-percent-cutting-guidance-lease-termination\" target=\"_blank\">Sabra Health Care REIT sinks 3.2% after cutting guidance on lease termination</a> (Nov. 5)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410479\" data-linked=\"BofAML turns bearish on Sabra, bullish on Omega Healthcare\" data-tweet=\"$SBRA $SBRA $OHI - BofAML turns bearish on Sabra, bullish on Omega Healthcare https://seekingalpha.com/news/3410479-bofaml-turns-bearish-on-sabra-bullish-on-omega-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3410479-bofaml-turns-bearish-on-sabra-bullish-on-omega-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410470\" data-ts=\"1542376316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410470-nomura-starts-adobe-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura starts Adobe at Buy</a></h4><ul>\n<li>Nomura Instinet <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+NomuraInstinet+Starts+Adobe+%28ADBE%29+at+Buy/14837658.html\" target=\"_blank\">starts</a> Adobe (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) at Buy with a $315 target.</li>\n<li>Analyst Christopher Eberle sees Adobe as \"a true content creation and global collaboration platform leveraging its massive sprawl of customer behavioral data to drive its best-in-class operating model.\"</li>\n<li>The analyst notes that Adobe helps \"businesses of all shapes and sizes continue to digitally transform\" and will be a \"significant partner\" for \"many years to come.\"</li>\n<li>Adobe shares are <font color=\"red\">down 1.3%</font> premarket to $236.88.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410470\" data-linked=\"Nomura starts Adobe at Buy\" data-tweet=\"$ADBE - Nomura starts Adobe at Buy https://seekingalpha.com/news/3410470-nomura-starts-adobe-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3410470-nomura-starts-adobe-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410463\" data-ts=\"1542375363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLOB\" target=\"_blank\">GLOB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410463-globantminus-4-despite-q3-beats-in-line-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globant -4% despite Q3 beats, in-line guide</a></h4><ul> <li>Globant (NYSE:<a href='https://seekingalpha.com/symbol/GLOB' title='Globant'>GLOB</a>) <font color=\"red\">drops 4.3%</font> premarket despite Q3 results that beat EPS and revenue estimates with $0.46 and $134.57M (+23% Y/Y), respectively. In-line Q4 guidance has revenue of $138M to $140M (consensus: $136.38M) and EPS of $0.45 to $0.49 (consensus: $0.48).</li>\n<li>\n<a href=\"https://seekingalpha.com/pr/17336000-globant-reports-2018-third-quarter-financial-results\" target=\"_blank\">Press release</a> / <a href=\"https://seekingalpha.com/article/4222702-globant-s-glob-ceo-martin-migoya-q3-2018-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a>.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410266-globant-beats-0_02-beats-revenue\" target=\"_blank\">Globant beats by $0.02, beats on revenue</a> (Nov. 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410463\" data-linked=\"Globant -4% despite Q3 beats, in-line guide\" data-tweet=\"$GLOB - Globant -4% despite Q3 beats, in-line guide https://seekingalpha.com/news/3410463-globantminus-4-despite-q3-beats-in-line-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3410463-globantminus-4-despite-q3-beats-in-line-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410462\" data-ts=\"1542375361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRN\" target=\"_blank\">TRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410462-trinity-industries-to-accelerate-buybacks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trinity Industries to accelerate buybacks</a></h4><ul> <li>Trinity Industries (NYSE:<a href='https://seekingalpha.com/symbol/TRN' title='Trinity Industries Inc.'>TRN</a>) announces that it entered into an accelerated share       repurchase program with JPMorgan to repurchase $350M worth of shares. The company says the accelerated share repurchase program will complete its current       share repurchase authorization for an aggregate of $500M of stock.</li>\n<li>Trinity plans to fund the ASR with       proceeds received from an increase in borrowing under a loan agreement.</li>     <li>Trinity also posts a guidance ahead, saying it expects full-year EPS of $1.15 to $1.35 vs. $0.90 to $1.10 prior and $1.11 consensus. The lower share count from the new buyback activity accounts for the higher EPS.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/17336452-trinity-industries-inc-announces-accelerated-share-repurchase-program-updates-2019-earnings\" target=\"_blank\">Press Release</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410462\" data-linked=\"Trinity Industries to accelerate buybacks\" data-tweet=\"$TRN - Trinity Industries to accelerate buybacks https://seekingalpha.com/news/3410462-trinity-industries-to-accelerate-buybacks?source=tweet\" data-url=\"https://seekingalpha.com/news/3410462-trinity-industries-to-accelerate-buybacks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410458\" data-ts=\"1542374527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410458-citi-defends-amat-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi defends AMAT after earnings</a></h4><ul>\n<li>Citi adds Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>) to its \"semis shopping list\" after the earnings report caused the Street to reset expectations for 1H19.</li>\n<li>Analyst Atif Malik says the risk-reward balance now looks more attractive for the next year and longer.</li>\n<li>Malik notes that the report was in-line with the firm's preview driven by \"incremental silicon weakness due to China Fujian export ban and mobile display weakness\" but sees a \"modest cut\" in the Q2 guidance.</li>\n<li>Source: Bloomberg First Word.</li>\n<li>AMAT shares are <font color=\"red\">down 9%</font> premarket to $31.86.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3410275-amat-minus-3-percent-downside-guide-near-term-headwinds\" target=\"_blank\">AMAT -3% on downside guide, near-term headwinds</a> (Nov. 15)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410458\" data-linked=\"Citi defends AMAT after earnings\" data-tweet=\"$AMAT - Citi defends AMAT after earnings https://seekingalpha.com/news/3410458-citi-defends-amat-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3410458-citi-defends-amat-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410437\" data-ts=\"1542372556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410437-viacomplus-4-on-beats-paramount-strength\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viacom +4% on beats, Paramount strength</a></h4><ul>\n<li>        Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a>) beats profit and revenue estimates for Q4 with a reported $0.99 and $3.49B.</li>\n<li>               Revenue breakdown: Media Networks, $2.52B (consensus: $2.53B); Filmed Entertainment, $984M (consensus: $871.4M). </li>\n<li>Paramount revenue jumped 25% Y/Y to $984M with $38M in operating profit compared to last year's lack of a profit. The seventh consecutive quarter of Y/Y gains was driven by the new <em>Mission Impossible</em>, <em>A Quiet Place</em>, and <em>Book Club</em>.</li>\n<li>               <a href=\"https://seekingalpha.com/pr/17336356-viacom-reports-strong-fourth-quarter-full-year-results\" target=\"_blank\">Press release</a>.  </li>\n<li>               VIAB is <font color=\"green\">up 4%</font> premarket to $33.10.  </li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3410413-viacom-beats-0_03-beats-revenue\" target=\"_blank\">Viacom beats by $0.03, beats on revenue</a> (Nov. 16)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410437\" data-linked=\"Viacom +4% on beats, Paramount strength\" data-tweet=\"$VIA $VIA $VIAB - Viacom +4% on beats, Paramount strength https://seekingalpha.com/news/3410437-viacomplus-4-on-beats-paramount-strength?source=tweet\" data-url=\"https://seekingalpha.com/news/3410437-viacomplus-4-on-beats-paramount-strength\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410435\" data-ts=\"1542372517\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HD\" target=\"_blank\">HD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410435-home-depotminus-2-after-baml-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Home Depot -2% after BAML cut</a></h4><ul> <li>Bank of America Merrill Lynch downgrades Home Depot (NYSE:<a href='https://seekingalpha.com/symbol/HD' title='Home Depot, Inc.'>HD</a>) to a Neutral rating after having it locked in at a Buy for a long stretch.</li> <li>The firm thinks 2018 was the peak in earnings growth for the home improvement retailer and 2017 was the peak in comparable sales.</li> <li>\"While HD has consistently outperformed broader home improvement industry growth, we believe that the beats may get smaller, which may keep investors on the sidelines,\" warns the BAML analyst team.</li> <li>BAML lowers its price objective on Home Depot to $195 from $219.</li> <li>Shares of Home Depot are <font color=\"red\">down 1.75%</font> in premarket trading to $174.25 vs. the 52-week trading range of $166.06 to $215.43.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410435\" data-linked=\"Home Depot -2% after BAML cut\" data-tweet=\"$HD - Home Depot -2% after BAML cut https://seekingalpha.com/news/3410435-home-depotminus-2-after-baml-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3410435-home-depotminus-2-after-baml-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410427\" data-ts=\"1542371494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410427-goldman-clearly-wrong-on-nvidia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman &quot;clearly wrong&quot; on Nvidia</a></h4><ul> <li>Goldman Sachs<a href=\"https://www.bloomberg.com/news/articles/2018-11-16/nvidia-results-prompt-mea-culpa-at-clearly-wrong-goldman-sachs\" target=\"_blank\"> removes</a> Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) from its conviction list after earnings, saying it was \u201cclearly wrong on the stock.\u201d</li> <li>The firm underestimated a channel inventory build and a correction in the gaming division. It sees the gaming correction as a \u201cone-time reset\u201d that could \u201ctake a few quarters before the market regains confidence in the growth trajectory of the business.\u201d </li> <li>Rating maintained at Buy since the company still \u201chas access to one of the best growth opportunity in Semis\u201d and a \u201csustainable competitive lead.\u201d</li>\n<li>Nvidia shares are <font color=\"red\">down 17.7%</font> premarket to $166.50.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3410310-nvidia-minus-17-percent-downside-guide-crypto-boom-ends\" target=\"_blank\">Nvidia -17% on downside guide as crypto boom ends</a> (Nov. 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410427\" data-linked=\"Goldman &quot;clearly wrong&quot; on Nvidia\" data-tweet=\"$NVDA - Goldman &quot;clearly wrong&quot; on Nvidia https://seekingalpha.com/news/3410427-goldman-clearly-wrong-on-nvidia?source=tweet\" data-url=\"https://seekingalpha.com/news/3410427-goldman-clearly-wrong-on-nvidia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>119&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410423\" data-ts=\"1542370961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410423-astrazenecas-imfinzi-flunks-late-stage-study-in-first-line-metastatic-lung-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s Imfinzi flunks late-stage study in first-line metastatic lung cancer</a></h4><ul>\n<li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) is down <font color=\"red\">3%</font> premarket on light volume following its <a href=\"https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-the-phase-iii-mystic-trial-of-imfinzi-and-tremelimumab-in-stage-iv-non-small-cell-lung-cancer16112018.html\" target=\"_blank\">announcement </a>of unsuccessful results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02453282?titles=mystic&amp;lead=astrazeneca&amp;rank=1\" target=\"_blank\">MYSTIC</a>, evaluating Imfinzi (durvalumab) alone and in combination with tremelimumab compared to standard-of-chemo in treatment-naive patients with Stage IV (metastatic) non-small cell lung cancer &#40;NSCLC&#41;.</li>\n<li>The study failed to demonstrate that either the monotherapy or combo therapy improved overall survival &#40;OS&#41; compared to chemo in patients with at least 25% PD-L1 expression, although patients in the monotherapy arm experienced 24% less risk (hazard ratio = 0.76) of cancer progression or death (p=0.036).</li>\n<li>Three other Phase 3 studies assessing durvalumab and tremelimumab, PEARL, NEPTUNE and POSEIDON, in first-line Stage IV  NSCLC are ongoing.</li>\n<li>Durvalumab is a PD-L1 inhibitor. Tremelimumab is a CTLA-4 inhibitor.</li>\n<li>Imfinzi is currently approved in more than 40 countries for Stage III (locally advanced) NSCLC.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410423\" data-linked=\"AstraZeneca&#39;s Imfinzi flunks late-stage study in first-line metastatic lung cancer\" data-tweet=\"$AZN - AstraZeneca&#39;s Imfinzi flunks late-stage study in first-line metastatic lung cancer https://seekingalpha.com/news/3410423-astrazenecas-imfinzi-flunks-late-stage-study-in-first-line-metastatic-lung-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3410423-astrazenecas-imfinzi-flunks-late-stage-study-in-first-line-metastatic-lung-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410421\" data-ts=\"1542370360\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BEDU\" target=\"_blank\">BEDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410421-bright-scholar-updates-on-buybacks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bright Scholar updates on buybacks</a></h4><ul> <li>Bright Scholar Education (NYSE:<a href='https://seekingalpha.com/symbol/BEDU' title='Bright Scholar Education'>BEDU</a>) announces that it repurchased 3,009,655 of its ADSs for an aggregate purchase price of approximately $37.2M.</li>\n<li>The buybacks were made between the adoption of the company's share repurchase program in April and November 15.</li> <li>Bright Scholar plans to continue to execute on its 2018 share repurchase program - subject to market conditions, the working capital requirements, general business conditions and other factors. The company says it may consider raising the buyback limit if necessary.</li>\n<li>BEDU  <font color=\"green\">+2.93%</font> after hours to  $10.88.</li>  <li>Source: <a href=\"https://seekingalpha.com/pr/17336317-bright-scholar-continues-execute-share-repurchase-program\" target=\"_blank\">Press Release</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410421\" data-linked=\"Bright Scholar updates on buybacks\" data-tweet=\"$BEDU - Bright Scholar updates on buybacks https://seekingalpha.com/news/3410421-bright-scholar-updates-on-buybacks?source=tweet\" data-url=\"https://seekingalpha.com/news/3410421-bright-scholar-updates-on-buybacks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410415\" data-ts=\"1542369817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410415-shire-presents-new-late-stage-data-on-hae-med-lanadelumab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire presents new late-stage data on HAE med lanadelumab</a></h4><ul> <li>Shire plc (NASDAQ:<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a>) <a href=\"https://seekingalpha.com/pr/17336264-shire-announces-new-help-study-tm-data-lanadelumab-hae-2018-acaai-annual-scientific-meeting\" target=\"_blank\">announces </a>additional data from the Phase 3 HELP study evaluating subcutaneously administered TAKHZYRO (lanadelumab) for preventing hereditary angioedema &#40;HAE&#41; attacks. The results will be presented at the ACAII Annual Scientific Meeting in Seattle, WA.</li> <li>The data showed that patients receiving 300 mg of lanadelumab every two weeks experienced significantly fewer HAE attacks, were less likely to have moderate or severe HAE attacks and were less likely to need rescue medication.</li>\n<li>A long-term extension study is ongoing.</li> <li>Lanadelumab is a monoclonal antibody the inhibits an enzyme called plasma kallikrein which plays a key role in HAE.</li> <li>The FDA approved TAKHZYRO in August. The European Commission should OK it this quarter.</li> <li>Shares are down <font color=\"red\">1%</font> premarket on light volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3410415\" data-linked=\"Shire presents new late-stage data on HAE med lanadelumab\" data-tweet=\"$SHPG - Shire presents new late-stage data on HAE med lanadelumab https://seekingalpha.com/news/3410415-shire-presents-new-late-stage-data-on-hae-med-lanadelumab?source=tweet\" data-url=\"https://seekingalpha.com/news/3410415-shire-presents-new-late-stage-data-on-hae-med-lanadelumab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410408\" data-ts=\"1542367827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCM\" target=\"_blank\">HCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410408-chi-meds-phase-iii-faluca-trial-for-fruquintinib-fails-to-meet-primary-endpoint-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chi-Med&#39;s phase III  FALUCA trial for fruquintinib fails to meet primary endpoint; shares down 17% premarket</a></h4><ul> <li>Hutchison China MediTech (NASDAQ:<a href='https://seekingalpha.com/symbol/HCM' title='Hutchison China MediTech Ltd.'>HCM</a>) is down <font color=\"red\">17%</font> on <a href=\"https://seekingalpha.com/pr/17336262-chi-med-announces-phase-iii-faluca-trial-results-fruquintinib-third-line-advanced-non-small\" target=\"_blank\">announcing</a> the outcome of FALUCA, its Phase III trial of fruquintinib in advanced non-small cell lung cancer patients in China who had failed two lines of systemic chemotherapy.</li>   <li>The trial did not meet the primary endpoint demonstrating a statistically significant increase in overall survival compared to placebo.</li>  <li>However, a significant improvements were observed in all secondary endpoints including progression-free survival, objective response rate, disease control rate and duration of response as compared to the placebo.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3410408\" data-linked=\"Chi-Med&#39;s phase III  FALUCA trial for fruquintinib fails to meet primary endpoint; shares down 17% premarket\" data-tweet=\"$HCM - Chi-Med&#39;s phase III FALUCA trial for fruquintinib fails to meet primary endpoint; shares down 17% premarket https://seekingalpha.com/news/3410408-chi-meds-phase-iii-faluca-trial-for-fruquintinib-fails-to-meet-primary-endpoint-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3410408-chi-meds-phase-iii-faluca-trial-for-fruquintinib-fails-to-meet-primary-endpoint-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410398\" data-ts=\"1542365454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RWLK\" target=\"_blank\">RWLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410398-rewalk-robotics-prices-11_6m-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ReWalk Robotics prices $11.6M public offering</a></h4><ul> <li>ReWalk Robotics (NASDAQ:<a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a>) <a href=\"https://seekingalpha.com/pr/17336282-rewalk-robotics-announces-pricing-11_6-million-public-offering\" target=\"_blank\">prices</a> its public offering of 38,660,722 units at a price of $0.30 per unit, for gross proceeds of ~$11.6M. Each unit contains one ordinary share and one common warrant to purchase one ordinary share.</li>       <li>Underwriters over-allotment is an additional 5,799,108 shares and/or warrants.</li>  <li>Net proceeds will be used for market development activities and broadening third-party payor coverage, (ii) R&amp;D costs related to developing its lightweight \u201csoft suit\u201d exoskeleton technology, and repayment of certain outstanding indebtedness and other related payments to Kreos Capital V (Expert Fund) Limited.</li> <li>Closing date is November 20.</li> <li>\n<strong>Update</strong>: Shares are down <font color=\"red\">47%</font> on robust volume early in the session.</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3410398\" data-linked=\"ReWalk Robotics prices $11.6M public offering\" data-tweet=\"$RWLK - ReWalk Robotics prices $11.6M public offering https://seekingalpha.com/news/3410398-rewalk-robotics-prices-11_6m-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3410398-rewalk-robotics-prices-11_6m-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3410394\" data-ts=\"1542364763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRO\" target=\"_blank\">FRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3410394-frontline-beats-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frontline beats by $0.06, beats on revenue</a></h4><ul>\n<li>Frontline (NYSE:<a href='https://seekingalpha.com/symbol/FRO' title='Frontline Ltd.'>FRO</a>): Q3 Non-GAAP EPS of -$0.05 <span style=\"color:green\">beats by $0.06</span>; GAAP EPS of $0.01 <span style=\"color:green\">beats by $0.12</span>.</li>\n<li>Revenue of $89.21M (+17.6% Y/Y) <font color=\"green\">beats by $7.46M</font>.</li>\n<li>Shares <font color=\"green\">+2.41%</font> PM.</li>\n<li><a href=\"https://seekingalpha.com/pr/17336269-fro-third-quarter-nine-months-2018-results\">Press Release</a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3410394\" data-linked=\"Frontline beats by $0.06, beats on revenue\" data-tweet=\"$FRO - Frontline beats by $0.06, beats on revenue https://seekingalpha.com/news/3410394-frontline-beats-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3410394-frontline-beats-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":71,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}